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Chapter 1    
 
General introduction 
 
1.1  Herbal medicinal product 
Herbal medicinal products are medicines consisting of medicinal plant materials, algae, 
macroscopic fungi, and combinations. They are sometimes called crude drug, botanical drugs, herbal 
drug, or herbal substance. The herbal medicinal products consisting of some kinds of plant materials 
are called as drug preparations or herbal preparations. 
Kampo medicine is a typical herbal medicinal product in Japan. In 2014, the gross production 
amount of Kampo medicine in Japan is 158 billion Japanese yen which accounts for 2.3% of the gross 
production amount of all medicinal products made in Japan (Japan kampo medicines manufactures 
association; JKMA, 2017). Use of 148 kinds of Kampo medicines is covered as by the health insurance 
in Japan (JKMA, 2016). Kampo medicine is important for health of Japanese nation. 
While, the United States food and drug administration (FDA) approved the only two botanical 
drugs Veregen and Fulyzaq in 2006 and 2012, respectively. Veregen is a proprietary extract of 
Camellia sinensis Kuntze and is use as a treatment for genital and perianal warts (Austin, 2006). 
Fulyzaq is a proprietary extract of the blood-red latex of Croton lechlerii Müll and is a novel indication 
for HIV-associated diarrhea (Austin, 2013). In use, the procedure of new drug application for herbal 
medicinal product is almost same as of chemical medicines (FDA, 2016). It is difficult to be approved 
because it would be difficult to manufacture herbal medicinal products assured their efficacy at the 
same level as chemical medicines.  
 
1.2  Quality control of herbal medicinal product 
International conference on harmonization of technical requirements for registration of 
pharmaceuticals for human (ICH) guides following four categories of quality, safety, efficacy, and 
multidisciplinary to medicinal manufacturing. Herbal medicinal product manufacturing complied with 
the guides of ICH would be required, too. 
However, quality control of herbal medicinal products like Kampo medicines are difficult than 
chemical medicines because most of their raw materials of herbal medicinal products are made from 
natural products that are a part of plant, animal, fungi, or mineral. Qualities of natural products are 
affected by species used, cultivation, processing, storage, and/or shipping conditions and methods, etc. 
Quality standards of over one hundred of crude drugs are provided by the Japanese 
Pharmacopoeia (Ministry of health, labour and welfare in Japan; MHLW, 2016a). The Japanese 
Pharmacopoeia prescribes origin (species, part, guiding component content), description, 
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identification (chemical test), purity, total ash, and acid-insoluble ash. Some drug companies use crude 
drugs complied with the Japanese Pharmacopoeia as ingredients of Kampo medicines in Japan. 
Additionally, currently good agricultural and collection practice (GACP) is applicable as a 
production process control of botanical raw materials of herbal medicinal products. 
 
1.3  Species identification of botanical raw materials 
Medicinal use of correct species prescribed by national/regional regulations like the Japanese 
pharmacopoeia (MHLW, 2016a) is the most important. In 2004, the side effects caused by the misuse 
of the crude drugs with some resemblances of the crude drug names was informed (MHLW, 2014). 
Aristolochia manshuriensis was used instead of Akebia quinata or A. trifoliata as crude drug Mutong 
(木通, written in Chinese character), Aristolochia fangchi was used instead of Sinomenium actum as 
Fungji (防已, written in Chinese character), or Aristolochia yunnanensis was used instead of Saussurea 
lappa as Muxiang (木香, written in Chinese character). Aristrolochia species contain aristolochic acid 
causing the Aristolochia nephropathy. Herbal medicinal product produced from wrong species might 
have not only the medicinal effect but also have toxicity. Use of correct species as a raw material is 
the pharmaceutical company’s responsibility. 
To use correct species as a botanical raw material, accurate species identification is necessary. 
Until now, species of raw materials were identified mainly by their morphological and chemical 
characteristics. Accurate species identifications of raw materials are difficult because the raw materials 
usually made of a part of plant those are dried root, rhizome, or leaf. They have little useful information 
for species identification. It is hard to identify species from the root morphology or chemical 
constituents because related species may have the similar root morphology or chemical constituents. 
 
1.4  Species identification using molecular markers for quality assurance of botanical raw 
materials 
In the 1980s, the molecular phylogeny has progressed at rapid speed with DNA analysis 
technology. Coupled with that, the DNA sequence data of many organisms was accumulated and 
genetic polymorphisms were observed between species, variety, or cultivar that are minimum units of 
taxon. In these situation, it was considered that the accurate species identification would be possible 
comparing the species-specific DNA polymorphisms obtained by using molecular makers. 
Therefore, in following 6 issues concerning the quality assurances of botanical raw materials, 
availabilities of the species identifications using molecular makers were evaluated.  
Identification of scientific name of medicinal plant 
Taxonomic position and scientific name of medicinal plant should be recognized accurately to 
understand medicinal properties of the medicinal plant. 
Cnidium officinale is cultivated for medicinal uses in Japan and called “Senkyu (川芎, written in 
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Chinese character)” in Japanese. Their rhizomes are used for a crude drug for sedative and analgesic 
effects, etc. While, in China, Ligusticum chuanxiong called “Chuanxiong (川芎, written in Chinese 
character)” was used medicinally. Cnidium officinale is described only in the Japanese Pharmacopoeia 
(MHLW, 2016c), Ligusticum chuanxiong is only in the Chinese Pharmacopoeia (Chinese 
Pharmacopeia Commission, 2015a). 
In taxonomic literatures, the medicinal plant “Senkyu” was first recognized as Conioselinum sp. 
by Yabe (1902). Makino (1908) described it as Cnidium officinale without stating any reason of 
classifying in the genus Cnidium. Hara (1954) suggested that C. officinale should be recombined to 
another genus but without mentioning about any appropriate genus. Kitagawa (1963) classified C. 
officinale in the genus Ligusticum because the gross morphology of C. officinale was similar to 
Ligusticum jeholense Nakai et Kitag. Suk et al. (1974) classified C. officinale to the genus 
Conioselinum based on their comparative anatomy of unripe fruit. Hatano et al. (1970) suggested that 
C. officinale was a diploid of hybrid origin between two allied species by their karyotype of the somatic 
chromosomes and meiosis in pollen mother-cells. Additionally, C. officinale and L. chuanxiong 
approximately had the same metabolic profiling (Kobayashi et al., 2012). The discordance in 
taxonomic position of Cnidium officinale is mainly because no ripe fruit of C. officinale has been 
observed. Morphology of ripe fruit is the most important characters for delimiting genera of Apiaceae.  
In this thesis, rbcL nucleotide sequences was used to infer taxonomic position of Cnidium 
officinale. Additionally, to identify the parent species of C. officinale, the multiple clones of internal 
transcribed spacer on nuclear ribosomal DNA (ITS) in an individual plant of C. officinale was obtained 
by cloning, sequenced, and compared with the ITS sequences of related species. 
Species identification for botanical raw material consisting of multiple origins 
In the Japanese Pharmacopoeia (MHLW, 2016a), many crude drugs consist of multiple origins. 
That means that some kinds of related species are possible to use as the same crude drug. Qualities of 
botanical raw materials would be different by species in detail. 
Licorice（甘草） is one of them. Licorice consists of three species of Glycyrrhiza uralensis, G. 
glabra, and G. inflate (Chinese Pharmacopeia Commission, 2015c). Additionally, the various 
combinations of hybrids among Glycyrrhiza species have been reported (Ashurmetov, 1996). 
Although the root morphological studies of these Glycyrrhiza species have been reported (Fujita et al., 
1951; Zeng et al., 1988), as a fact, it was difficult to identify species based on the morphologies of 
dried roots or rhizomes used as crude drugs. 
In this thesis, to identify accurately original species of licorice, the four kinds of DNA regions of 
ITS, rbcL, maturase K gene for lysine (matK), and trnH– psbA intergenic region (trnH: tRNA histidine 
gene, psbA: protein D1 code gene of Photosystem II) were researched. Species and hybrids were 
identified and mapped in China by the genotypes obtained from the research. Additionally, 
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relationships among medicinally used Glycyrrhiza species were presumed by their phylogenic analysis. 
Confirmation of chemical properties of botanical raw materials identified by molecular markers 
Understanding chemical properties of botanical raw materials by original species were essential 
for quality assurance of herbal medicinal product manufacturing. Then, for licorice, availability of 
chemical properties presumed by species identified using molecular markers for the quality assurance 
was evaluated. 
Constituent properties of licorices have been reported about eleven kinds of constituent contents 
for the licorices on the markets (Yoneda et al., 1990; Yoneda et al., 1991), the high performance liquid 
chromatography (HPLC) patterns of licorices cultivated in botanical garden in Japan (Shibano et al., 
1996; Kitagawa et al., 1998), and species-specific constituents of glycycoumarin, glabridin, or 
licochalcone A (Shibata and Saitoh, 1978; Hatano et al., 1991; Hayashi et al., 2000). 
In this thesis, to confirm chemical properties of medicinally used Glycyrrhiza species identified 
from the above genotypes, six kinds of main constituent contents and three species-specific constituent 
contents of 205 licorices were researched by each original species. 
Historical study of an important crude drug 
The licorice root stored in Shosoin (正倉院, written in Chinese character) since 756AD is a 
national treasure. The Shosoin-licorice was investigated morphologically at the first scientific 
investigation of Shosoin-medicaments (Fujita et al., 1955), and was assigned to Glycyrrhiza glabra 
var. glandulifera. As an appendix of the first investigation program of Shosoin-medicaments, one of 
the present authors performed the HPLC analysis of Shosoin-licorice to identify its characteristic 
species-specific flavonoid constituents (Shibata, 1991). However, the result of HPLC analysis was not 
so satisfactory, since the species-specific flavonoids in Shosoin-licorice were missing during the 
storage of more than 1250 years.  
In this thesis, species identification of the Shosoin-licorice was attempted based on species 
identification and confirmation of chemical properties for licorice above. 
Development of an easier discriminating method 
To conduct species identification using molecular markers, high-priced device like DNA 
sequencer is used. To popularize species identification using molecular markers, an easier 
discrimination method without a high-priced DNA sequencer were required as a purity test to stop 
commingling of Atractylodes lancea rhizome (蒼朮, written in Chinese character) with Atractylodes 
rhizome (白朮, written in Chinese character) on the Japanese Pharmacopoeia (MHLW, 2016b). 
Discrimination between Atractylodes rhizome and Atractylodes lancea rhizome using molecular 
markers of ITS or trnK have been reported (Cheng et al., 1997; Mizukami et al., 2000). This purity 
test based on the amplification refractory mutation system (ARMS) detected the differences of 
nucleotide sequences on ITS among the medicinal Atractylodes species (Guo et al., 2006). The ARMS 
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required rigorous experimental condition comparatively because the ARMS detected the nucleotide 
substitution by existence or nonexistence of polymerase chain reaction (PCR) products using the 
specific mismatch primer. 
In this thesis, to discriminate between Atractylodes rhizome and Atractylodes lancea rhizome, 
PCR restriction fragment length polymorphism (PCR-RFLP) as a simple, quick, and stable method 
was attempted. 
Exclusion of fake raw material 
Fake raw materials would be distributed on the market or mixed in a lot of raw materials (MHLW, 
2014). Discrimination and exclusion of fake raw materials are essential for quality assurance of herbal 
medicinal manufacturing. Crude drugs of Tiannanxing ( 天南星 , written in Chinese character) 
resembles Banxia (半夏, written in Chinese character) derived from Araceae species closely and 
sometimes distributes as Banxia or is mixed within Banxia on the markets. 
In this thesis, discrimination between Banxia and Tiannanxing by their rbcL sequences and 
exclusion of Tiannanxing from Banxia were attempted.  
 
1.5  Operating procedure of species identification on GACP or GMP 
Species identification for botanical raw materials should be examined systematically at suitable 
timings on GACP or good manufacturing practice (GMP). Therefore, operating procedure of the 
species identifications mentioned above on GACP or GMP in herbal medicinal product manufacturing 
was considered. Especially, GACP as production process control is important because botanical raw 
materials are natural product and their qualities would be strongly affected from the production process. 
Additionally, Japanese pharmaceutical companies would have little GACP experiences but have many 
GMP experiences. They would be currently at the phase of thinking about a way to carry out GACP 
control. 
In this thesis, the international guides concerning GACP were reviewed at first. Next, a suitable 
GACP was proposed based on the reviews. Finally, operation procedure of the species identification 
on the suitable GACP or GMP was proposed. 
 
1.6  Objectives of this thesis 
One of the purpose of this thesis is availability assessments for the molecular makers using 
species identification.  
Next purpose is availability assessments for the species identification using molecular markers 
for herbal medicinal product manufacturing based on the studies of the following 6 issues. The 6 issues 
were; (1) identification of scientific name of medicinal plant, (2) species identification for botanical 
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raw material consisting of multiple origins, (3) confirmation of chemical properties of botanical raw 
materials identified by molecular markers, (4) historical study of an important crude drug, (5) 
development of an easier discriminating method, (6) exclusion of fake raw material. 
Last purpose is reviewing of GACP and operation procedure of the species identification on 
GACP or GMP for herbal medicinal product manufacturing. 
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Chapter 2  
  
Identification of scientific name of medicinal plant using molecular makers 
 
Phylogenetic relationship of medicinally important Cnidium officinale and Japanese Apiaceae 
based on rbcL sequences and ITS cloning analysis 
 
2.1  Introduction 
Cnidium officinale Makino is cultivated for medicinal uses in Japan and called “Wa-Senkyu (和
川芎, written in Chinese character)” in Japanese. Their rhizomes are used for a crude drug for sedative 
and analgesic effects, etc. Senkyu produced about 400 t every year in Japan and are important both 
medicinally and economically. Japanese botanists considered that C. officinale was introduced in 
Japan from China (Kimura et al., 1961). But, C. officinale is not listed in current Chinese flora (Chang, 
1985). In China, a species resembled C. officinale is cultivated for medicinal uses, too. Those scientific 
name is Ligusticum chuanxiong Hort. ex Qiu et al. (Qiu et al., 1979) and called the same crude drug 
name “Chuanxiong (川芎, written in Chinese character)” in Chinese or “Kara-Senkyu (唐川芎, written 
in Chinese character)” in Japanese. As Senkyu or Chuanxiong (川芎, written in Chinese character), 
Cnidium officinale is described only in the Japanese Pharmacopoeia (MHLW, 2016c), Ligusticum 
chuanxiong is only in the Pharmacopoeia of the People's Republic of China (Chinese Pharmacopeia 
Commission, 2015a). 
In taxonomic literatures, the medicinal plant “Senkyu” was first recognized as Conioselinum sp. 
by Yabe (1902). Makino (1908) described it as Cnidium officinale without stating any reason of 
classifying in the genus Cnidium. Hara (1954) suggested that C. officinale should be recombined to 
another genus but without mentioning about any appropriate genus. Kitagawa (1963) classified C. 
officinale in the genus Ligusticum because the gross morphology of C. officinale was similar to 
Ligusticum jeholense Nakai et Kitag. which was distributed in the northeast China but the two-species 
had the different morphologic characteristics in petal, involucral bract, and hair on leaflet. Suk et al. 
(1974) classified C. officinale to the genus Conioselinum based on their comparative anatomy of 
unripe fruit. Hatano et al. (1970) suggested that C. officinale was a diploid of hybrid origin between 
two allied species by their karyotype of the somatic chromosomes and meiosis in pollen mother-cells. 
Accurate identification of the taxonomic position and the scientific name of a crude drug is 
essential to understand its pharmacological feature. About Cnidium officinale, two crude drugs having 
the same name “Senkyu (川芎, written in Chinese character)” and  approximately the same metabolic 
profiling (Kobayashi et al. 2012) in Japan and China were classified into the two genera of Cnidium 
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or Ligusticum. The clarification of taxonomic position of medicinally important C. officinale and the 
taxonomic relationship of C. officinale and L. chuanxiong is important pharmacologically. 
The discordance in taxonomic position of Cnidium officinale is mainly because no ripe fruit of 
C. officinale has been observed. Morphology of ripe fruit is the most important characters for 
delimiting genera of Apiaceae. To identify the taxonomic position of Cnidium officinale, it is 
necessary to explore any other taxonomic characters instead of the fruit morphology. 
In the 1990s, nucleotide sequence polymorphisms of the large subunit of ribulose-1, 5- 
bisphosphate carboxylase/oxygenase gene (rbcL) have been employed for phylogenetic analyses in 
various plant taxa and proved to be useful in clarifying the phylogenetic relationships among genera 
(Soltis et al., 1993; Xiang et al., 1993; Morgan et al., 1994). 
In this study, rbcL nucleotide sequences was used to infer taxonomic position of Cnidium 
officinale and phylogenetic relationships of genera of subfamily Apioideae where C. officinale might 
belong. The genera in Apioideae have been classified into the five tribes based on their fruit 
morphologies (Yamazaki, 1982). The rbcL sequences of representative genera in the five tribes of 
Apioideae including Cnidium, Ligusticum, and Conioselinum where C. officinale have been classified 
were determined and compared with the rbcL sequence of C. officinale. 
Additionally, Liu et al. (2002) suggested that the scientific name of Cnidium officinale should be 
changed to Ligusticum chuanxiong in their phylogenetic study based on ITS and matK. ITS from 
nuclear nrDNA was multicopy and inherited parentally (Álvarez et al., 2003). Cnidium officinale 
presumed being a diploid hybrid (Hatano et al., 1970) might have two kinds of the parental ITS in an 
individual plant. Therefore, in this study, to identify the parent species of C. officinale, the multiple 
ITS clones in an individual plant of C. officinale was obtained by cloning, sequenced, and compared 
with the ITS sequences of related species. 
 
2.2  Materials and methods 
rbcL nucleotide sequencing 
The rbcL sequences of 30 species which represent the 24 genera of the three subfamilies; 
Hydrocotyloideae, Saniculideae, and Apioideae in Apiacea were determined (Table 2.1). Apioideae 
included the five tribes; Scandiceae, Symrnieae, Amineae, Peucedanaeae, and Dauceae recognized 
by Yamazaki (1982). In addition, the rbcL sequences of one species each of four genera in Araliaceae 
and one species each in Pittosporaceae, Cornaceae, and Caprifoliaceae were determined as outgroups 
based on the following considerations. Takhtajan (1980) and Cronquist (1988) considered that 
Araliaceae was a sister group of Apiaceae. Judd et al. (1994) pointed out the close relationship 
between Pittosporaceae and the Araliaceae/Apiaceae Complex. According to the phylogenetic 
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research using the rbcL sequence data by Chase et al. (1993), the genus Corokia in Cornaceae and 
Viburnum in Caprifoliaceae are clustered with Apiaceae. These rbcL sequences data of Corokia 
cotoneaster and Viburnum acerifolia deposited in DDBJ nucleotide sequence database were used. The 
other 35 rbcL sequences were newly determined in this study. 
Total DNA was extracted from fresh leaves as described by Doyle et al. (1987). The two 
overlapping DNA fragments (A and B in Fig. 2.2) covering most of the rbcL gene were amplified by 
the polymerase chain reaction using the primers A-F and A-R for fragment A, and B-F and B-R for 
fragment B (Table 2.2). These fragments were sequenced using the Taq DyeDeoxy Terminator Cycle 
Sequencing Kit and 373A DNA sequencer (Applied Biosystems Division, PERKIN ELMER). For the 
sequencing, the twelve internal primers were used (Fig. 2.2, Table 2.2). These primers were 
synthesized based on the Nicotiana tabacum rbcL gene (Shinozaki et al., 1986) and were modified 
specifically for Apiaceae. 
Phylogenetic analysis was performed on 1224 base pairs of the rbcL gene between 58 and 1281 
from the start codon of Nicotiana tabacum rbcL gene using Phylogenetic analysis using parsimony 
(PAUP) version 3.1.1 (Swofford, 1993). 
The phylogenetic analysis was conducted through a heuristic search with the tree bisection 
reconnection (TBR) branch swapping and MULPARS option. Multiple islands of equally most 
parsimonious trees were searched heuristically with 500 random sequence additions and a strict 
consensus tree of the most parsimonious trees obtained was constructed. The consistency index (Kluge 
et al., 1969) and the retention index (Farris, 1989) for a strict consensus tree were calculated. 
To evaluate confidences for clustering groups in a strict consensus tree, the bootstrap analysis 
(Felsenstein, 1985; Hillis et al., 1993) and the decay analysis (Chase et al., 1993; Morgan et al., 1994) 
were conducted. The bootstrap and decay analyses were conducted for the representative 30 taxa 
because the taxa except these 30 taxa always clustered with the one of 30 taxa in the preliminary 
analyses. The bootstrap analysis was conducted through a heuristic search with TBR branch swapping, 
MULPARS, and 1,000 bootstrap resampling. The decay analysis was conducted through a heuristic 
search with TBR branch swapping, MULPARS, and 500 random sequence additions and confirmed 
trees having one or two steps longer variables than the most parsimonious trees. 
ITS cloning analysis 
Cnidium officinale, Ligusticum chuanxiong, and six species that referred to the relations with C. 
officinale or L. chuanxiong in the previous rbcL sequence research were used for the ITS cloning 
analysis (Table 2.3). Total DNA was extracted using the DNAeasy Plant Mini Kit (Qiagen) from the 
dried leaf of an herbarium specimen. Fourteen of cloned ITS were obtained respectively from Cnidium 
officinale or Ligusticum chuanxiong each by the pT7Blue Perfectly Blunt® Cloning Kit (Novagen). 
The cloned ITS of C. officinale or L. chuanxiong and the ITS of related species were amplified using 
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the universal primers by White et al. (1990). The PCR reaction mixture was: 10xEx-Buffer (TaKaRa) 
5μl, dNTP mix (TaKaRa) 5μl, forward primer (10 pmol/μl), 1.0μl, reverse primer (10 pmol/μl) 1.0μl, 
template DNA 1.25μl, Ex-Taq (TaKaRa) 0. 25μl, DMSO 5μl, D.D.W. 31.5μl. The PCR cycle was: 
(94℃, 1 min; 48℃, 2 min; 72℃, 3 min) x 30 cycles, (72℃, 7 min) x 1 cycle. The amplified DNA was 
purified by the GFX® PCR DNA and Gel Band Purification Kit (Amersham biotech). The purified 
DNA was sequenced by the BigDye Terminator Cycle Sequencing Kit ver.2.0 and using the Model 
3100 automated sequencer (Applied Bio Systems). Based on the ITS sequences obtained, a strict 
consensus tree of the most-parsimonious trees of equal length were computed after a heuristic search 
of trees using the TBR and MULPARS options. (Swofford, 1993). 
 
2.3  Results 
Phylogenetic relationships of Apiaceae species based on the rbcL sequences 
Phylogenetic analysis resulted in 420 most parsimonious trees with 360 steps with relatively high 
values of the consistency index of 0.67 and the retention index of 0.75. The strict consensus tree of 
the 420 trees was illustrated in Fig. 2.3. The heuristic searches for the bootstrap and decay analyses 
resulted in 24 most parsimonious trees with 235 steps. For the decay analyses, 236 trees with 236 steps 
or 27,902 trees with 237 steps were found respectively. The bootstrap percentage (b) and decay index 
(d) were indicated in the strict consensus tree of the 24 most parsimonious trees with 235 steps (Fig. 
2.4). 
In the strict consensus trees (Figs. 2.3 and 2.4), subfamily Apioideae clustered to a monophyletic 
group. The monophyly of subfamily Apioideae were supported with the high confidence indices (b = 
100, d >= 3). In the cluster of subfamily Apioideae, the three groups were recognized and were 
compared with the tribes classified by Yamazaki (1982). The first group in the subfamily Apioideae 
consisted of Pleurospermum. This group corresponded to the tribe Smyrnieae sensu. The second group 
consisted of Bupleurum species with the high confidence indices (b = 100, d >= 3). Bupleurum has 
simple leaves with parallel venations which is a unique characteristic in Apiaceae. Bupleurum was 
classified in tribe Ammineae. The last group consisted of the other Apioideae species with the low 
confidence indices (b = 54, d = 1). 
In the last group of the subfamily Apioideae, the following three subgroups were recognized with 
the middle level of confidence indices (b = 65 or 53, d = 2). The first subgroup consisted of the four 
genera of Cryptotaenia, Sium, Cicuta, and Oenanthe were classified in tribe Ammineae. The second 
subgroup consisted of the eight genera classified in the four different tribes; (1) Osmorhiza and Torilis 
in tribe Scandiceae, (2) Ostericum in tribe Peucedanaeae, (3) Pternopetalum, Spuriopimpinella, 
Tilingia, and Ligusticum scoticum in tribe Ammineae, and (4) Daucus in tribe Dauceae. The last 
subgroup consisted of the 12 genera classified in the three different tribes; (1) Heracleum, 
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Conioselinum, Peucedanum, Angelica, Glehnia, and Coelopleurum in tribe Peucedanaeae, (2) 
Foeniculum, Chamaele, Libanotis, Ligusticum sinense, Ligusticum jeholense and Cnidium officinale 
in tribe Ammineae, and (3) Anthriscus in tribe Scandiceae.  
The strict consensus trees based on the rbcL sequences supported monophyly of subfamily 
Apioideae (Drude, 1898). The tribal classification of East Asian Apioideae (Table 2.1) have been 
accepted by several taxonomists (Kitagawa, 1982; Yamazaki, 1982; Pimenov, 1987), except Shan 
(1979) who applied Scandicineae (De Candole, 1830) instead of Smyrnieae and Scandiceae (Koch 
1824). In the monophyletic Apioideae, the clustering based on the rbcL sequences was discordant with 
the traditional tribal classification based mainly on their fruit morphologies and illustrated polyphylies 
of tribes Scandiceae, Ammineae, and Peucedanaeae. 
Taxonomic position of Cnidium officinale based on the rbcL sequences 
In the strict Consensus tree based on the rbcL sequences (Figs. 2.3 and 2.4), Cnidium officinale 
clustered with Ligusticum chuanxiong, L. sinense (藁本, written in Chinese character), and L. jeholense 
(遼藁本, written in Chinese character) distributed in China. Cnidium officinale had the same rbcL 
sequence of L. chuanxiong and there is only one base substitution of the rbcL sequence between C. 
officinale and L. sinense or L. jeholense. On the other hand, Cnidium officinale did not cluster with 
Cnidium japonicum or Conioselinum species where Suk et al. (1974) classified C. officinale based on 
their unripe fruit morphology. 
The results suggested that Cnidium officinale had close relationships to the Chinese Ligusticum 
species, especially to L. chuanxiong. When it was assumed that Cnidium officinale belonged to 
Cnidium or Conioselinum, the length of the most parsimonious trees increased six or three steps, 
respectively. Hence it is difficult to accept that Cnidium officinale is classified in Cnidium or 
Conioselinum. 
ITS cloning analysis of Cnidium officinale 
The 14 of ITS clones obtained from an individual plant of Cnidium officinale or Ligusticum 
chuanxiong respectively, and ITS of the six kinds of related species were sequenced (Fig. 2.5). The 
ITS clones of C. officinale and L. chuanxiong showed approximately the same clustering feature and 
had mainly two kinds of genotypes in the strict consensus tree based on the ITS sequences (Fig. 2.6). 
The ITS clones of C. officinale or L. chuanxiong having the two genotypes divided into the two clusters 
by each genotype. One of them clustered with Ligusticum jeholense, the other clustered with 
Ligusticum sinense. Within the L. jeholense cluster, 0-2 substitutions in the ITS sequences were 
observed between C. officinale and L. chuanxiong, and 1-2 substitutions between L. jeholense and C. 
officinale, or between L. jeholense and L. chuanxiong. Within the L. sinense cluster, 0-2 substitutions 
in the ITS sequences were observed between C. officinale and L. chuanxiong, and 0-5 substitutions 
between L. sinense and C. officinale, or between L. sinense and L. chuanxiong.  
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Cnidium officinale or L. chuanxiong presumed that they were diploid hybrids (Hatano et al., 
1970). They had the two ITS genotypes each in an individual plant. One ITS genotype was similar to 
the ITS genotype of L. jeholense, the other was similar to L. sinense. It suggested that C. officinale or 
L. chuanxiong would be hybrid between L. jeholense and L. sinense, or their closely related species. 
Ligusticum sinense and L. jeholense are distributed in China and used as the crude drugs “Gaoben 
(藁本, written in Chinese character)” and “Liao-Gaoben (遼藁本, written in Chinese character)”, 
respectively (Fig. 2.1). Cnidium officinale or Ligusticum chuanxiong might be new medicinal plants 
generated by artificial hybridizations between the existing medicinal plants. 
 
2.4  Discussion 
Taxonomic position and Scientific name of Cnidium officinale 
The strict consensus tree based on the rbcL sequences (Fig. 2.3) showed that Cnidium officinale 
related closely with Ligusticum chuanxiong, L. sinense, and L. jeholense. Additionally, the ITS cloning 
analysis of C. officinale or L. chuanxiong suggested that the two species would be hybrid between L. 
jeholense and L. sinense, or their closely related species. In these results, it was reconfirmed 
genetically that C. officinale related closely to L. chuanxiong. This conclusion agreed with Kitagawa 
(1963) who renamed Cnidium officinale Makino to Ligusticum officinale (Makino) Kitagawa, but 
neither with Yabe (1902) and Suk et al. (1974) who classified it in Conioselinum, nor with Makino 
(1908) who classified it in Cnidium. 
However, Liu et al. (2002) suggested that the scientific name of Cnidium officinale should be 
changed to Ligusticum chuanxiong, C. officinale should be renamed L. officinale but not L. chuanxiong 
because some morphological, chemical, and genetically differences were observed between C. 
officinale and L. chuanxiong. 
On the other hand, Ligusticum scoticum did not cluster with Ligusticum chuanxiong, L. sinense, 
L. jeholense distributed in China but with genus Ostericum, Pternopetalum, Spuriopimpinella, Tilingia, 
Daucus, and Torilis (Fig. 2.2). The genus Ligusticum was polyphyletic. It was considered that the 
genus name of Ligusticum chuanxiong, L. sinense, L. jeholense should be changed because Ligusticum 
scoticum is the type species of the genus Ligusticum (Linnaeus, 1753) and L. scoticum has taxonomical 
priority using the genus name of Ligusticum.  
From the rbcL sequence and ITS cloning analyses, the aspects of medicinally important Cnidium 
officinale were defined that C. officinale did not belong to genus Cnidium but to genus Ligusticum and 
had close relationship to L. chuanxiong with the almost same hybridized origin. This definition should 
be referred when the crude drug Senkyu or Chuanxiong （川芎） were used in Japan or China. 
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Table 2.1.  Plant materials for the rbcL sequencing. Subfamilial and tribal classifications of Apiaceae 
were based on Yamazaki (1982). The rbcL sequence data from D44552 to D44590 were 
deposited in the DDBJ, EMBL and NCBI nucleotide sequence databases. 
 
species                          source, voucher, and DNA accession number 
Apiacea 
 Hydrocotyloideae 
   Centella asiatica (L.) Urban Matsuzaki, Shizuoka, Japan; THS36331; D44559 
   Hydrocotyle sibthorpioides Lam.* Naraha, Fukushima, Japan; THS38155; D44570 
 Saniculideae 
   Sanicula chinensis Bunge Mt. Yamizo, Ibaraki, Japan; THS36340, D44585 
 Apioideae 
  Scandiceae 
   Anthriscus aemula Schischkin* Mt. Yamizo, Ibaraki, Japan; THS36339; D44554 
   Osmorhiza aristanata Makino et Yabe* Matsuzaki, Shizuoka, Japan; THS36335; D44578 
   Torilis japonica (Houtt.) DC. Shimazuma, Ibaraki, Japan; THS36337; D44590 
   Smyrnieae 
   Pleurospermum camtschaticum Hoffm.* Souya, Hokkaido, Japan; THS37755; D44583 
  Amineae 
   Bupleurum fruticosum L.* Cult. at Tsumura & Co.; THS38161; D44556 
   Bupleurum longeradiatum Turcz. 
   subsp. sachalinense Kitag. var. elatius Kitag.*  Geibikei, Iwata, Japan; THS37853; D44557 
   Bupleurum scorzonerifolium Wild. 
   var. stenophyllum Nakai* Cult. at Tsumura & Co.; THS38157; D44558 
   Chamaele decumbens Makino* Odaka, Fukushima, Japan; THS36352; D44560 
   Cicuta virosa L.* Hanazono, Ibaraki, Japan; THS36355; D44561 
   Cnidium japonicum Miq.* Hitachi, Ibaraki, Japan; THS36366; D44562 
   Cnidium officinale Makino* Cult. at Tsumura & Co.; THS38159; D44586 
   Cryptotaenia japonica Hassk.* Oshino, Yamanashi, Japan; THS36686; D44565 
   Foeniculum valgare Mill.* Cult. at Tsumura & Co.; THS38158; D44567 
   Libanotis coreana Kitag. f. ugoensis Kitag.* Kisakata, Akita, Japan; THS35370; D44573 
   Ligsticum chuanxiong Hort. ex Qiu et al. Qingcheng, Sichuan, China; THS38154; D44572 
   Ligsticum jeholense Nakai et Kitag. Nanjing Botanical Garden, China; D44574 
   Ligsticum scoticum L. subsp. hultenii Hulten* Hirono, Fukushima, Japan; THS36105; D44575 
   Ligsticum sinese Oliv.* Mt. Emei, Sichuan, China; THS3814; D44576 
   Oneanthe javanica DC.* Shimozuma, Ibaraki, Japan; THS36337; D44577 
   Pternopetalum tanakae Hand.-Mazz. Azumi, Nagano, Japan; THS36369; D44584 
   Sium serra (Franch. et Savat.) Kitag.* Hanazono, Ibaraki, Japan; THS36357; D44587 
   Spuriopimpinella calycina (Maxim.) Kitag. Okutama, Tokyo, Japan; THS37771; D44588 
   Tilingia ajanensis Regel Nenakusa, Gunma, Japan; THS36690; D44589 
  Peucedanaeae 
   Angelica dahurica (Fisch.) Benth. et Hook.* Okutsu, Kumamato, Japan; THS36189, D44553 
   Coelopleurum gmelinii (DC.) Ledeb.* Souya, Hokkaido, Japan; THS37757; D44563 
   Glehnia littoralis Fr. Schm. ex Miq. Hanazono, Ibaraki, Japan; THS36372; D44579 
   Peucedanum japonicum Thunb. ex Murr.* Matsuzaki, Shizuoka, Japan; THS36332; D44581 
  Dauceae 
   Daucus carota L. var. sativa DC. Matsuzaki, Shizuoka, Japan; THS36694; D44566 
Araliaceae 
 Aralieae 
   Aralia cordata Thunb.* Ookuma, Fukushima, Japan; THS36681; D44555 
   Panax japonicas C. A. Mayer* Ookuma, Fukushima, Japan; THS36651; D44571 
 Schefflereae 
   Acantopanax sciadophylloides Franch. et Savat.* Hanazono, Ibaraki, Japan; THS36358; D44552 
   Kalopanax pictus (Thunb.) Nakai* Odaka, Fukushima, Japan; THS36351; D44571 
Caprifoliaceae 
   Viburunum acerifolia L. Olmstead et al., 1992; L01959 
Cornaceae 
   Corokia cotoneaster Raoul Xiang et al. 1993; L11221 
Pittosporaceae 
   Pittosporum tobira (Thunb. ex Murr.) Aiton Matsuzaki, Shizuoka, Japan; THS36333; D44582 
 
Abbreviations used: Cult. = cultivated, THS = Tsumura herbarium specimen. Asterisks indicate 
species used for the bootstrap and decay analyses. 
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Table 2.2.  Locations and base compositions of the amplification and sequencing primers for rbcL 
gene. 
 
Primer                       Sequence (5’ to 3’)                         Location 
for the DNA fragments A and B amplification 
 A-F ATG  TCA  CCA  CAA  ACA  GAG  ACT  AAA  GC 1 - 26 
 A-R CCC  TTT  TCA  TCA  TTT  CTT  CAC  ATG  TAC  760 - 734 
 B-F TGA  AAA  CGT  GAA  TTC  CCA  ACC  GTT  TAT  GCG 609 - 1360 
 B-R CCA  TAC  TTC  ACA  AGC  AGC  AGC  TAG  TTC 1386 - 1360 
for the DNA fragments A and B sequencing 
 1F AAG  CAG  GTG  TTG  GAT  TCA  CAG  C 23 - 44 
 2F CTT  GAT  CGT  TAC  AAA  GGG  CG 229 - 248 
 3F TGG  CAT  CCA  AGT  TGA  GAG  AG 459 - 478 
 4F TTC  TTA  TTT  TGT  GCC  GAA  GC 652 - 671 
 5F GCA  TGC  AGT  TAT  TGA  TAG  AAC 891 - 910 
 6F GTC  TCT  CTA  CCA  GGT  GTT  CT 1087 - 1106 
 1R AGA  TCA  CGC  CCC  TCA  TTA  CG 1310 - 1291 
 2R GGT  GAA  ATA  AAT  ACC  GCG  AC 1095 - 1076 
 3R GAA  GTA  GGC  CAT  TAT  CTC  G 871 - 853 
 4R CCC  TTT  TCA  TCA  TTT  CTT  CAC  ATG  TAC 760 - 734 
 5R TTA  GGT  TTA  ATA  GTA  CAT  CCC  AAC  AG 530 - 505 
 6R AGG  TCT  AAT  GGG  TAA  GCT  AC 320 - 301 
 
The location numbers correspond to the location number of Nicotiana tabacum rbcL (Shinozaki et 
al., 1986). 
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Table 2.3.  Plant materials for the ITS cloning analysis. Sixteen ITS were cloned from Cnidium 
officinale or Ligusticum chuanxiong, respectively.  
 
Scientific name Locality DNA No. 
Angelica sinensis (Oliv.) Diels China 1048 
Cnidium officinale Makino (cloned, 01-14) Hokkaido, Japan; THS897 1036 
Conioselinum filicinum (H. Wolff) H. Hara Fukushima, Japan; THS803 1037 
Ligustichum sinensis Oliv. (1) Sichuan, China; THS39680 1061 
Ligustichum sinensis Oliv. (2) China; THS61723 1125 
Ligustichum sinensis Oliv. (3) Sichuan, China; THS65104 1127 
Ligusticum chuanxiong Hort. (cloned, 01-14) Sichuan, China; THS70994 1047 
Ligusticum jeholense (Nakai & Kitag.) Nakai & Kitag. (1) Jiangsu BG., China; THS462 1039 
Ligusticum jeholense (Nakai & Kitag.) Nakai & Kitag. (2) Liaoning, China; THS63133 1128 
Ligusticum pteridophyllum Franchet Yunnan, China; THS63134 1121 
Ligusticum tenuissimum (Nakai) Kitagawa Liaoning, China; THS949 1031 
 
THS meant Tsumura herbarium specimen. DNA No. was the managed by Dr. H. Yamaji in Tsumura 
& Co. 
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Cnidium officinale  (和川芎)        Ligusticum chuanxiong  (唐川芎) 
               
          
 
 
Ligusticum sinense  (藁本)         Ligusticum jeholense (遼藁本) 
       
         
 
Figure 2.1.  Dried rhizomes of medicinal parts and leaves of Cniduum officinale, Ligusticum 
chuanxiong, L. sinense, and L. jeholense. The plant names written in Chinese 
characters were indicated in parentheses. 
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Figure 2.2.  Relatevie positions of the twelve sequencing primers for the rbcL sequencing. A and B 
were DNA fragments amplificated for the rbcL sequencing. Arrows were the twelve 
sequencing primers and indicated the direction of strand synthesis. 
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Figure 2.3.  Strict consensus tree of 420 most parsimonious trees with 360 steps each resulting from 
the phylogenetic analyses of rbcL sequences. Asterisks indicate species used for 
bootstrap and decay analyses. The acronyms in right hand side show the tribes of 
Apioideae (Yamazaki, 1982): Sc = Scandiceae, Sy = Symrnieae, A = Amminaeae, Pe = 
Peucedanaeae, and Da = Dauceae. 
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Figure 2.4.  Strict consensus tree of 24 most parsimonious tree with 235 steps for 30 taxa. Bootstrap 
percentage (b) and decay index (d) were indicated below each branch. The acronyms in 
right hand side mean the tribes of Apioideae (Yamazaki, 1982): Sc = Scandiceae, Sy = 
Symrnieae, A = Amminaeae, Pe = Peucedanaeae, and Da = Dauceae. 
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C_officinale_05   .................a...a....................t.....t.......c.............c..................g..g....... 
C_officinale_06   .................a...a..........................t.......c.............c......t...........g..g....... 
C_officinale_07   .................a...a..........................t.......c.............c......t...........g..g....... 
C_officinale_08   .................a...a..........................t.......c.............c......t...........g..g....... 
C_officinale_09   .................a...a..................................c.............c..................g..gt...... 
C_officinale_10   .................a...a..........................t.......c.............c......t...........g..g....... 
C_officinale_11   .........c.......a...a..........................t.......c.............c......t...........g..g....... 
C_officinale_12   .................a...a..........................t.......c.............c......t...........g..g....... 
C_officinale_13   .................a...a..........................t.......c.............c......t...........g..g....... 
C_officinale_14   .................a...a..........................t.......c.............c..................g..g....... 
C_filicinum       .................a................................................t...c..................g..g....... 
L_sinensis_1      .................a...a..................................c.............c..................g..g....... 
L_sinensis_2      .................a...a..................................c.............c..................g..gt...... 
L_sinensis_3      .................a...a..................................c.............c..................g..g....... 
L_chuanxiong_01   .................a...a..........................t.......c.............c..................g.......... 
L_chuanxiong_02   .................a...a..........................t.......c.............c..................g.......... 
L_chuanxiong_03   .................a...a..........................t.......c.............c..................g..g....... 
L_chuanxiong_04   .................a...a..................................c.............c..................g..gt...... 
L_chuanxiong_05   .................a...a..................................c...g.........c..................g..gt...... 
L_chuanxiong_06   .................a...a..................................c.............c..................g..gt...... 
L_chuanxiong_07   .................a...a..........................t.......c.............c..................g.......... 
L_chuanxiong_08   .................a...a..................................c.............c..................g..gt...... 
L_chuanxiong_09   .................a...a..................................c.............c..................g..gt...... 
L_chuanxiong_10   .................a...a..................................c.............c..................g..gt...... 
L_chuanxiong_11   .................a...a..........................t.......c.............c..................g.......... 
L_chuanxiong_12   .................a...a..................................c.............c..................g..gt...... 
L_chuanxiong_13   .................a...a..........................t.......c.............c..................g.......... 
L_chuanxiong_14   .................a...a..........................t.......c.............c..................g.......... 
L_jeholensis_1    .................a...a..........................t.......c.............c..................g..g....... 
L_jeholensis_2    .................a...a..........................t.......c.............c..................g..g....... 
L_pteridophyllum  ........................................................c.............t..................g..g....... 
L_tenuissimum     ........t........a................................................t.a.c..................g..g....... 
 
 
 
Figure 2.5.  ITS sequences of Cnidium officinale and related species. The ITS 
sequences of Cnidium officinale (01-14) or Ligusticum chuanxiong (01-
14) were cloned from the one individual plant, respectively. 
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              210       220       230       240       250       260       270       280       290       300 
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
A_sinensis        ccaaaacacaacgactctcgacaacggatatctcggctctcgcatcgatgaagaacgtagcgaaatgcgatacttggtgtgaattgcagaatcccgtgaa 
C_officinale_01   .................................................................................................... 
C_officinale_02   .................................................................................................... 
C_officinale_03   .................................................................................................... 
C_officinale_04   .................................................................................................... 
C_officinale_05   .................................................................................................... 
C_officinale_06   ..............................c..................................................................... 
C_officinale_07   .......................................a............................................................ 
C_officinale_08   .................................................................................................... 
C_officinale_09   ...................................................g................................................ 
C_officinale_10   .................................................................................................... 
C_officinale_11   .................................................................................................... 
C_officinale_12   .................................................................................g.................. 
C_officinale_13   .................................................................................................... 
C_officinale_14   ............................................................t....................................... 
C_filicinum       .................................................................................................... 
L_sinensis_1      .................................................................................................... 
L_sinensis_2      .................................................................................................... 
L_sinensis_3      .................................................................................................... 
L_chuanxiong_01   .................................................................................................... 
L_chuanxiong_02   .................................................................................................... 
L_chuanxiong_03   ................................................................................................a... 
L_chuanxiong_04   .................................................................................................... 
L_chuanxiong_05   .................................................................................................... 
L_chuanxiong_06   .................................................................................................... 
L_chuanxiong_07   .................................................................................................... 
L_chuanxiong_08   .................................................................................................... 
L_chuanxiong_09   .................................................................................................... 
L_chuanxiong_10   .................................................................................................... 
L_chuanxiong_11   .................................................................................................... 
L_chuanxiong_12   .................................................................................................... 
L_chuanxiong_13   .................................................................................................... 
L_chuanxiong_14   .................................................................................................... 
L_jeholensis_1    .................................................................................................... 
L_jeholensis_2    .................................................................................................... 
L_pteridophyllum  .................................................................................................... 
L_tenuissimum     .................................................................................................... 
 
 
 
              310       320       330       340       350       360       370       380       390       400 
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
A_sinensis        ccatcgagtctttgaacgcaagttgcgcccgaagccattaggctgagggcacgtctgcctgggtgtcacgcatcatctttgcccacaaccactcactcct 
C_officinale_01   ...................................a...............................................a........a....... 
C_officinale_02   ...................................................................................a........a....... 
C_officinale_03   ...................................................................................a........a....... 
C_officinale_04   ...................................................................................a........a....... 
C_officinale_05   ...................................................................................a........a....... 
C_officinale_06   ...................................................................................a........a....... 
C_officinale_07   ...................................................................................a........a....... 
C_officinale_08   ...................................................................................a........a....... 
C_officinale_09   ...................................................................................a........a....... 
C_officinale_10   ...................................................................................a........a....... 
C_officinale_11   ...................................................................................a........a....... 
C_officinale_12   ...................................................................................a........a....... 
C_officinale_13   ...................................................................................a........a....... 
C_officinale_14   ...................................................................................a........a....... 
C_filicinum       .....................................c.............................................................. 
L_sinensis_1      ...................................................................................a........a....... 
L_sinensis_2      ...................................................................................a........a....... 
L_sinensis_3      ...................................................................................a........a....... 
L_chuanxiong_01   ...................................................................................a........a....... 
L_chuanxiong_02   ...................................................................................a........a....... 
L_chuanxiong_03   ...................................................................................a........a....... 
L_chuanxiong_04   ...................................................................................a........a....... 
L_chuanxiong_05   ...................................................................................a........a....... 
L_chuanxiong_06   ...................................................................................a........a....... 
L_chuanxiong_07   ...................................................................................a........a....... 
L_chuanxiong_08   ...................................................................................a........a....... 
L_chuanxiong_09   ...................................................................................a........a.t..... 
L_chuanxiong_10   ...................................................................................a........a....... 
L_chuanxiong_11   ...................................................................................a........a....... 
L_chuanxiong_12   ...................................................................................a........a....... 
L_chuanxiong_13   ...................................................................................a........a....... 
L_chuanxiong_14   ...................................................................................a........a....... 
L_jeholensis_1    ...................................................................................a........a....... 
L_jeholensis_2    ...................................................................................a........a....... 
L_pteridophyllum  .............................t...................................................................... 
L_tenuissimum     .....................................c...................................g.................t........ 
 
 
 
Figure 2.5.  Continued.  
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              410       420       430       440       450       460       470       480       490       500 
         ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
A_sinensis        cgtggagctgtactggtatgggggcggaaattggcctcccgtgccttgttgtgcggttggcgcaaaagtgagtctccggcgacggacgtcgtgacattgg 
C_officinale_01   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_02   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_03   tcaa.......g.c...t.....-....................................t.....g..............................c.. 
C_officinale_04   tcaa.......g.c...t.....-....................................t....................................c.. 
C_officinale_05   tcaa.......g.c...t.....-............................................c.................t..........c.. 
C_officinale_06   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_07   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_08   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_09   tcaa.......g.c...t.....-....................................t....................................c.. 
C_officinale_10   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_11   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_12   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_13   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_officinale_14   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
C_filicinum       t.a........gtc...t..........................................t.......c.........a.......t............. 
L_sinensis_1      tcaa.......g.c...t.....-.........................................................................c.. 
L_sinensis_2      tcaa.......g.c...t.....-....................................t....................................c.. 
L_sinensis_3      tcaa.......g.c...t.....-.........................................................................c.. 
L_chuanxiong_01   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
L_chuanxiong_02   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
L_chuanxiong_03   tcaa.......g.c...t.....-t...........................................c...-.............t..........c.. 
L_chuanxiong_04   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
L_chuanxiong_05   tcaa.......g.c...t.....-....................................t....................................c.. 
L_chuanxiong_06   tcaa.......g.c...t.....-....................................t....................................c.. 
L_chuanxiong_07   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
L_chuanxiong_08   tcaa.......g.c...t.....-....................................t....................................c.. 
L_chuanxiong_09   tcaa.......g.c...t.....-....................................t....................................c.. 
L_chuanxiong_10   tcaa.......g.c...t.....-....................................t....................................c.. 
L_chuanxiong_11   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
L_chuanxiong_12   tcaa.......g.c...t.....-....................................t....................................c.. 
L_chuanxiong_13   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
L_chuanxiong_14   tcaa.......g.c...t.....-............................................c...-.............t..........c.. 
L_jeholensis_1    tcaa.......g.c...t.....-............................................c............................c.. 
L_jeholensis_2    tcaa.......g.c...t.....-............................................c............................c.. 
L_pteridophyllum  ..a........g.c...t.....-............................................c.......t.....t..............c.. 
L_tenuissimum     t.a........gtc...t.................................................tct...........................c.. 
 
 
 
510       520       530       540       550       560       570       580       590 
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.... 
A_sinensis        tggttgtaaaataccctcatgtcttgtcgcgcgaatccgcgtcatc---ttagtgagctcaaggacccttaggcggcacacactttgtgcactt 
C_officinale_01   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_02   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_03   ...........g................a........t........---...........t..a....c...............c.....g... 
C_officinale_04   ...........g................a........t........---...........t.......................c.....g... 
C_officinale_05   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_06   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_07   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_08   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_09   ...........g................a........t........---...........t.......c...............c.....g... 
C_officinale_10   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_11   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_12   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_officinale_13   ...........g................a........t........---...........t.......c.....a.........c....tg... 
C_officinale_14   ...........g................a........t........---...........t.......c.....a.........c.....g... 
C_filicinum       ...........g........................t.........atc...........t.......................c.....g... 
L_sinensis_1      ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_sinensis_2      ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_sinensis_3      ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_01   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_02   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_03   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_04   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_05   ...........g................a.......tt........---...........t.......c.....a.........c.....g... 
L_chuanxiong_06   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_07   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_08   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_09   ...........g................a...a....t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_10   ...........g................a.......tt........---...........t.......c.....a.........c.....g... 
L_chuanxiong_11   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_12   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_13   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_chuanxiong_14   ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_jeholensis_1    ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_jeholensis_2    ...........g................a........t........---...........t.......c.....a.........c.....g... 
L_pteridophyllum  ...........g...t............a..a....t.........---...........t.......................c.....g... 
L_tenuissimum     ...........g..........................t.......---...........t.......................c.....g... 
 
Figure 2.5.  Continued.  
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Figure 2.6.  Strict consensus tree of the most parsimonious trees based on the ITS sequences of 
Cnidium officinale and related species. The ITS sequences of Cnidium officinale and 
Ligusticum chuanxiong were obtained from the one individual plant by cloning, 
respectively. 
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Chapter 3 
 
Species identification using molecular makers  
for botanical raw materials consisting of multiple origins 
 
Species identification of licorice using nuclear ribosomal DNA and  
Chloroplast DNA genetic markers 
 
3.1 Introduction 
Licorice is one of the most useful herbs in traditional Chinese medicine and Japanese Kampo 
medicine. In the Chinese Pharmacopoeia, three species of Glycyrrhiza uralensis, G. glabra, and G. 
inflate are prescribed as licorice: (Chinese Pharmacopeia Commission, 2015c). In the Japanese 
Pharmacopoeia, two species of G. uralensis and G. glabra are prescribed (MHLW, 2016d). Although 
these Glycyrrhiza species are identified based on the morphologic characteristics of their aerial part, 
especially on their leaf and fruit morphologies (Zhang, 1998; Fig. 3.1), it is difficult to identify species 
accurately based on the morphologies of dried roots or rhizomes using medicinally. The species-
specific root morphologies of licorice (Fujita et al., 1951; Zeng et al., 1988), and component properties 
(Shibata et al., 1978; Hatano et al., 1991; Kitagawa et al., 1998; Shebang et al., 1996; Yonder et al., 
1990 and 1991) have been reported. Additionally, the various combinations of hybrids among 
Glycyrrhiza species have been reported (Ashurmetov, 1996). To stabilize pharmacological effect of 
herbal medicinal products including licorice, the accurate species identification is essential for the 
crude drug licorice consisting of multiple origins including hybrids because the species-specific 
component properties of licorice have been reported. 
About species identifications for crude drugs, species identification using molecular markers 
have been evaluated as a higher-accuracy method (Goda et al., 2003). The identifications of 
Glycyrrhiza species using RAPD, RFLP, or rbcL sequences on chloroplast DNA (cpDNA) have been 
reported (Yamazaki et al., 1994; Kakutani et al., 2001; Hayashi et al., 1998 and 2000). The species 
identification using only genetic markers on cpDNA would lead to a misidentification because cpDNA 
generally inherited uniparentally (Mogensen, 1996). Since genetic markers vary in their rates of 
nucleotide substitution and since there are intra specific variations in their nucleotide sequences, a 
selection of genetic markers with a unique nucleotide sequence for each species is needed for highly 
accurate species identification (Goda et al., 2003). 
Therefore, in this study, to identify accurately original species of crude drug licorice, the four 
kinds of DNA regions were researched for 205 Glycyrrhiza specimens. One of the four kinds of DNA 
regions were the ITS on nuclear ribosomal DNA (nrDNA). Since ITS is inherited from both parents, 
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ITS sequences can detect genetic information on both parents and hybrids (Baldwin et al., 1995). 
Three of the four kinds of DNA regions were the rbcL gene, the matK gene, and the trnH–psbA 
intergenic region on cpDNA. It is generally considered that they have different rates of nucleotide 
substitution those are known as evolution rates. The evolution rate of the rbcL gene is slower than that 
of the matK gene, or the trnH–psbA intergenic regions (Goda et al., 2003). Suitable genetic markers 
for the species identification of licorice could be selected from the genetic information of those four 
kinds of DNA regions.  
 
3.2  Materials and methods 
Materials 
The 205 herbarium specimens were identified based on their morphologic characteristics of the 
aerial part (Zhang et al., 1998). Three Glycyrrhiza species used as licorice (G. glabra: n = 51, G. 
inflata: n =18, and G. uralensis: n =128) and four Glycyrrhiza species as out-group (Glycyrrhiza 
echinata: n = 2, Glycyrrhiza lepidota: n = 1, Glycyrrhiza macedonika: n = 1, and Glycyrrhiza 
pallidiflora: n = 4) were included in the 205 specimens. The vouchers and localities of the 205 licorice 
specimens were listed (Table 3.1). The vouchers were deposited in the herbaria of Osaka University 
of pharmaceutical sciences (OY), Tsumura & Co. (THS), Tokyo University (TI), and Tohoku 
University (TUS) in Japan.  
DNA Sequencing 
Total DNA was extracted using the DNAeasy Plant Mini Kit (Qiagen) from a dried leaf on the 
herbarium specimen. The complete sequence of the ITS, the partial sequences of rbcL (168 bp), matK 
(143bp), and trnH–psbA (239bp) including nucleotide polymorphisms among the Glycyrrhiza species 
examined were amplified with PCR under the following conditions. The following amplifying primers 
were used for the ITS: ITS5; GGA AGT AAA AGT CGT AAC AAG G and ITS4; TCC TCC GCT 
TAT TGA TAT GC (White et al., 1990), for the rbcL: r662f; GTG CCG AAG CAA TTT ATA AAG C 
and r829r; TTG CAG TGA AAC CTC CAG TT, for the matK: 1242f; CTT CGA CAC TGG GTG 
AAA GAT G and m1384r; AGG AAC AAG AAT AAT CTT GG, or the trnH–psbA: trnH-forward; 
ACG GGA ATT GAA CCC GCG CA (Demesure et al., 1995) and Gly-trnHR1; CAT ATG ACT TCA 
CAA TGT AAA ATC. The PCR reaction mixture consisted of 10x Gene Taq Buffer 5µl (Nippon Gene), 
dNTP mix 4 µl (Nippon Gene), forward primer (10 pmol/ml) 2.5 µl, reverse primer (10 pmol/ml) 2.5 
µl, Gene Taq 1 µl (Nippon Gene), DMSO 5 µl, D. D. W. 25.75 µl, and template DNA 5 µl (5 ng). For 
the PCR cycle, the step-down PCR was applied (Kawakami et al., 1999). 
Electrophoresis was performed for the amplified DNA fragments through 1.2% TAE agarose gel. 
The amplified DNA fragments were cut from the agarose gel and purified using the GFX PCR DNA 
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and Gel Band Purification Kit (Amersham Biotech). The purified PCR products were sequenced using 
the BigDye Terminator Cycle Sequencing Kit ver.2.0 and a Model 3100 automated sequencer 
following the manufacturer’s instructions (Applied Biosystems). For sequencing the ITS, matK, and 
trnH–psbA, their amplifying primers were used as sequencing primers. For sequencing the rbcL, 
r694f: ACT GGT GAA ATC AAA GGG C and r809r: AAG TAG TCA TGC ATT ACG AT were 
designed as sequencing primers. 
Phylogenetic Analyses 
The phylogenetic analyses were carried out using the PAUP software package 3.1.1 (Swofford, 
1993). The most-parsimonious trees of equal length were computed after a heuristic search of trees 
using the TBR and MULPARS options. 
 
3.3  Results 
Variable nucleotide sites and genotypes of ITS, rbcL, matK, and trnH-psbA 
In the sequencing results of the four kinds of DNA regions for the 205 Glycyrrhiza specimens, 
the following nucleotide substitutions and the genotypes were observed (Table 3.2). On the ITS 
sequence (accession number AB280738 in GenBank), two variable sites were observed at the 187th 
and 411-413th nucleotides. The ITS genotypes were defined by the combinations with the nucleotide 
substitutions on the two variable sites, and were named as I-1(T, TGC), I-2 (T, CAA), I-3 (C, TGC), 
and ADD (Y, YRM). Within the ADD of ITS genotype, two kinds of nucleotides were observed at 
every variable site: Y (= C + T) at the 187th and YRM (Y = C + T, R = A + G, and M = A + C) at the 
411-413th nucleotides. The ADD genotype coincided with a combination of the I-2 (T, CAA) and I-3 
(C, TGC) genotypes. On the rbcL sequence (AB012126), two variable sites were observed at the 706th 
and 736th. The rbcL genotypes were named as R-1 (A, T) and R-2 (G, A). On the matK sequence 
(AB28074), a variable site was observed at the 568th-573rd. The matK genotypes were named as M-
1 (CTTATT) and M-2 (Deletion). On the trnH–psbA (AB280745), three variable sites were observed 
at the 72nd, 125th, and 171st. The trnH–psbA genotypes were named T-1 (C, A, T), T-2 (C, A, G), T-
3 (C, A, G), and T-4 (T, A, T). 
Total genotypes and their phylogenetic analysis 
In the 205 Glycyrrhiza species examined, the ten total genotypes (TG-1‒TG-9 and ADD) were 
recognized as combinations of the genotypes obtained from the ITS, rbcL, matK, and trnH–psbA. The 
total genotypes of 205 samples described in Table 3.1. The combinations of the ITS, rbcL, matK, and 
trnH–psbA genotypes and frequencies of each species identified by the morphological characteristics 
for the total genotype were illustrated in Fig. 3.2.  
In the 205 Glycyrrhiza species examined, all the out-group (n = 8) had the TG- 1 genotype. 
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Glycyrrhiza glabra identified by the morphologic characteristics had TG-2, TG-3, TG-7, TG-9, and 
ADD genotypes. The TG-3 genotype was the most observation in G. glabra (78% = 40/51). 
Glycyrrhiza inflata had the TG-2, TG-4, TG-5, and ADD genotypes. The TG-5 genotype was the most 
in G. inflata (78% = 14/18). Glycyrrhiza uralensis had the TG-4, TG-6, TG-7, TG-8, TG-9, and ADD 
genotypes. The TG-7, TG-8, and TG-9 genotypes dominated 91% (116/128) in G. uralensis. 
To define phylogenetic relationships among the total genotypes, a phylogenetic analysis was 
performed. In this result, only one most-parsimonious phylogenetic tree of eight steps in length was 
calculated based on the sequences of ITS, rbcL, matK, and trnH–psbA except samples having the 
ADD genotype (Fig. 3.2). The 17 samples having the ADD genotype were excluded from this 
phylogenetic analysis because they had two kinds of nucleotides at the same nucleotide substitution 
site. In the phylogenetic tree, two clades consisting of TG-2‒TG-5 or TG-6‒TG-9 were recognized. 
In the clade of TG-2‒TG-5, TG-4 and TG-5 formed a sub-clade. On the other hand, in the clade of 
TG-6‒TG-9, TG-8 and TG-9 formed a sub-clade. 
Species identification by the total genotypes 
Species-specific total genotypes were defined from the frequencies of species identified by 
morphological characteristics and from the phylogenetic relationships for the total genotypes (Fig. 
3.2). The TG-1 genotype was presumed as a specific genotype of the out group examined. TG-2 was 
of G. glabra or G. inflata, and did not identify which was G. glabra or G. inflata. TG-3 was of G. 
glabra. TG-4 was of G. glabra or G. inflata, and did not identify which was G. glabra or G. inflata 
because observed TG-4 was too small in number. Additionally, TG-4 was not of G. uralensis which 
was in another clade. TG-5 was of G. inflata. On the other hand, TG-6‒TG-9 clustering a clade in the 
phylogenetic tree were presumed as species-specific genotypes of G. uralensis. 
Additionally, licorices having the ADD genotype were presumed as hybrids between G. uralensis 
and either G. glabra or G. inflata because the ADD genotype might be mixed the I-2 with I-3 
genotypes of ITS (Table 3.2). The I-2 genotype was observed in the TG-2‒TG-5 of total genotypes 
that were presumed as the species-specific genotypes of G. glabra or G. inflata, and the I-3 genotype 
was observed in the TG-6‒TG-9 that were presumed as the species-specific genotypes of G. uralensis. 
In this study, the hybrid between G. glabra and G. inflata could not be detected because all of G. 
glabra and G. inflata examined had the same ITS genotype (I-2) and the mixtures of nucleotides on 
variable sites inferring the hybridization of the both species could not be observed in ITS. 
The consistency of licorice species identification based on the total genotypes and the 
morphological characteristics was indicated about 96% (197/205) in this study. The species 
identification of three samples were discordant on the two methods and five samples with TG-2 of the 
total genotype could not be distinguished between G. glabra and G. inflata. 
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3.4  Discussions 
Efficient molecular markers for species identification of Licorice 
The species identification of licorice was possible from the total genotype obtained from the 
nucleotide sequences of ITS on nrDNA, rbcL, matK, and trnH–psbA on cpDNA. Meanwhile, from 
this result, G. uralensis, G. glabra, or G. inflata was identified efficiently based on the genetic 
information only from ITS, matK, trnH–psbA but not need rbcL. G. uralensis was identified by the I-
3 genotype of ITS (Fig. 3.2). In the same, G. glabra or G. inflata was by I-2 genotype of ITS. 
Additionally, G. glabra was by the T-2 genotype of trnH–psbA. G. inflata was by the M-2 genotype 
of matK. 
Phylogenetic relationships among G. uralensis, G. glabra, and G. inflata 
Hayashi et al. (1998) have reported that G. uralensis was more closely related to G. inflata than 
to G. glabra because G. uralensis and G. inflata had the same rbcL sequence. The same rbcL sequence 
of G. uralensis and G. inflata (Hayashi et al., 1998) was equivalent to the R-2 genotype of rbcL in this 
study and the rbcL sequence of G. glabra was the R-1 genotype. On the phylogenetic tree in this study 
(Fig. 3.2), the R-1 genotype was observed in the clade of G. uralensis, G. glabra, or G. inflata, and 
the R-2 genotype was observed only in the clade of G. uralensis. Meanwhile, the phylogenetic tree 
based on the ITS, rbcL, matK, and trnH–psbA sequences clearly showed the two clades in the three 
Glycyrrhiza species using medicinally (Fig. 3.2). One clade consisted of G. glabra and G. inflata, the 
other of G. uralensis. That was suggested that G. glabra was closely related to G. inflata than to G. 
uralensis. 
In the clade of G. glabra and G. inflata, the TG-2 of total genotype was presumed as an ancestral 
genotype and remained in G. glabra and G. inflata. Later, G. glabra would acquire the nucleotide 
substitution from T to G at the 171th on trnH–psbA intergenic region (TG-3). In the same, G. glabra 
or G. inflata would acquire from T to G at the 72nd on trnH–psbA (TG-4). Additionally, G. inflata 
would acquire the deletion of the six nucleotides on matK (TG-5). On the other hand, the TG-6 was 
presumed as an ancestral genotype in G. uralensis. G. uralensis would acquire the nucleotide 
substation from T to G at the 171st on trnH–psbA (TG-7), or from A and T to G and A at the 706 and 
736th on rbcL respectively (TG-8) and from A to G at the 125th on trnH–psbA (TG-9). 
Distribution and expansion of the total genotype in China  
The 205 samples examined with the total genotypes were mapped for each province in China 
(Fig. 3.3). G. glabra or G. inflata with the TG-2–TG-5 of total genotypes distributed in northwestern 
China. On the other hand, G. uralensis with the TG-6–TG-9 genotypes distributed from northeastern 
to northwestern China. The hybrids between G. uralensis and either G. glabra or G. inflata with the 
ADD genotype were distributed in northwestern China where G. uralensis, G. glabra, and G. inflata 
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mix-distributed. 
The ancestral TG-2 genotype in G. glabra or G. inflata was only observed with the most of G. 
glabra and G. inflata examined in Xinjiang province. In G. uralensis, the four intra-specific variations 
of the total genotypes (TG-6–TG-9) were recognized. The ancestral TG-6 genotype in G. uralensis 
was observed in Xinjiang province. G. uralensis with TG-7–TG-9 genotypes were observed in wide 
areas from northeastern to northwestern China. Frequencies of TG-8 were comparatively higher in 
western China, especially in Xinjiang province. The TG-9 were higher in eastern China. From the 
distribution pattern and frequencies of the genotype, it might be considered that G. uralensis have 
expanded its distribution from western China to eastern China because the phylogenetic ancestral 
genotypes (TG-6 and TG-8) were distributed mainly in western areas and the derivative genotype (TG-
9) was in eastern areas in China. 
Morphological phenotypes and maternal species of hybrids 
In this study, the 17 samples with the ADD of the total genotype were observed. They were 
presumed hybrids between G. uralensis and either G. glabra or G. inflata. The morphological 
phenotypes or species identified by the morphological characteristics, and maternal species of these 
17 samples with the ADD genotype were reconfirmed (Table 3.3). The maternal species of the hybrids 
were presumed from the combinations of the genotypes of rbcL, matK, and trnH–psbA on cpDNA in 
the result of the phylogenetic analysis (Fig. 3.2). 
In the 17 hybrids with the ADD genotype, ten, six, or one hybrids have been identified as G. 
uralensis, G. glabra, or G. inflata by their morphological characteristics, respectively. From their 
cpDNA information, the maternal species of three in ten hybrids identified as G. uralensis, five in the 
six hybrids identified as G. glabra, and one hybrid identified as G. inflata were different from the 
species identified by morphological characteristics. It was suggested that the hybrids among G. 
uralensis, G. glabra, and G. inflata would have no species-specific hazard on their hybridizations and 
the morphological phenotype of hybrid would have no linkage with the maternal inheritance.  
Additionally, in G. glabra identified by morphological characteristics with the ADD genotype, 
four of G. inflata were recognized as the maternal species (THS498-1, 2, 3, and 4; Table 3.3). In this 
study, the hybrid between G. glabra and G. inflata could be not detected because G. glabra and G. 
inflata examined had the same ITS genotype (I-2). However, the four hybrids had the genotypes of G. 
uralensis and either G. glabra or G. inflata on ITS (ADD), G. inflata on matK (M-2) and trnH–psbA 
(T-3), and the morphological phenotype of G. glabra. It was suggested that cross-hybridizations 
among G. uralensis, G. glabra, and G. inflata would have occurred. 
Therefore, in the case of G. uralensis, G. glabra, and G. inflata are cultivated for medicinal use 
in the same field, a careful attention is required in the crude drug use because they would be easy to 
hybridize and difficult to identify their species or hybrids by their morphological phenotypes. 
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Table 3.1.  Species identified by the morphologic feature of the aerial part, vouchers, locations and 
the total genotypes (TG-1−TG-9 and ADD). 
 
OutGroup (n = 8) 
 
G. inflata (n = 18)  
 
voucher species locality genotype  voucher locality genotype  voucher locality genotype 
OY-7 G. echinata clutivated in OY TG- 1  THS72280 China, Xinjiang TG- 2  THS44521 China, Xinjiang TG- 8 
OY G. echinata clutivated in OY TG- 1  THS71515 China, Xinjiang TG- 2  THS44522 China, Xinjiang TG- 8 
OY-25 G. lepidota Canada TG- 1  THS66047-2 China, Xinjiang TG- 4  THS44523 China, Xinjiang TG- 8 
OY-18 G. macedonika Italy TG- 1  THS72281 China, Xinjiang TG- 5  THS44524 China, Xinjiang TG- 8 
OY-2 G. pallidiflora clutivated in OY TG- 1  THS72283 China, Xinjiang TG- 5  THS44525 China, Xinjiang TG- 8 
OY-3 G. pallidiflora clutivated in OY TG- 1  THS72284 China, Xinjiang TG- 5  THS40629 China, Xinjiang TG- 8 
OY-19 G. pallidiflora Hungary TG- 1  THS40630 China, Xinjiang TG- 5  THS42506 China, Xinjiang TG- 8 
OY-20 G. pallidiflora Russia TG- 1  THS40620 China, Xinjiang TG- 5  THS42508 China, Xinjiang TG- 8 
     THS502-1 China, Xinjiang TG- 5  THS72271 China, Xinjiang TG- 8 
     THS502-2 China, Xinjiang TG- 5  THS71543 China, Gansu TG- 8 
     THS503-3 China, Xinjiang TG- 5  THS42164 China, Nei Monggol TG- 8 
     THS43490 China, Xinjiang TG- 5  TUS133887 China, Nei Monggol TG- 8 
G. glabra (n = 51) 
 THS43491 China, Xinjiang TG- 5  THS72316-04 China, Nei Monggol TG- 8 
 THS43492 China, Xinjiang TG- 5  THS72316-05 China, Nei Monggol TG- 8 
 THS43493 China, Xinjiang TG- 5  THS31538 China, Hebei TG- 8 
voucher  locality genotype  THS43494 China, Xinjiang TG- 5  THS41989 China, Liaoning TG- 8 
THS66496  Spain TG- 2  THS71518 China, Gansu TG- 5  OY-1 clutivated in OY TG- 8 
THS66495  France TG- 2  THS71521 China, Gansu ADD  OY-8 clutivated in OY TG- 8 
OY-24  Egypt TG- 2      OY-12 clutivated in OY TG- 8 
OY-10  Russia TG- 3      OY-14 clutivated in OY TG- 8 
OY  Russia TG- 3  
G. uralensis (n = 128) 
 OY-15 clutivated in OY TG- 8 
TI  Russia TG- 3   OY-17 clutivated in OY TG- 8 
TUS134993  Russia TG- 3   OY clutivated in OY TG- 8 
THS758-1  Czechoslovakia TG- 3  voucher locality genotype  THS43132 Mongolia TG- 9 
THS758-2  Czechoslovakia TG- 3  THS43478 China, Xinjiang TG- 4  THS43133 Mongolia TG- 9 
THS758-3  Czechoslovakia TG- 3  THS41797 China, Xinjiang TG- 6  THS43134 Mongolia TG- 9 
THS758-4  Czechoslovakia TG- 3  THS500-4 China, Xinjiang TG- 7  THS43135 Mongolia TG- 9 
THS758-5  Czechoslovakia TG- 3  THS500-5 China, Xinjiang TG- 7  THS43136-1 Mongolia TG- 9 
THS491  Spain TG- 3  THS43478 China, Xinjiang TG- 7  THS43136-2 Mongolia TG- 9 
THS493-1  Spain TG- 3  TUS231103 China, Qinghai TG- 7  THS43137 Mongolia TG- 9 
THS493-2  Spain TG- 3  TUS231099 China, Qinghai TG- 7  THS43483 China, Xinjiang TG- 9 
THS493-3  Spain TG- 3  TUS231101 China, Qinghai TG- 7  THS71524 China, Gansu TG- 9 
THS493-4  Spain TG- 3  THS72314-02 China, Ningxia TG- 7  THS71528 China, Gansu TG- 9 
THS494-1  Spain TG- 3  THS72314-03 China, Ningxia TG- 7  THS71531 China, Gansu TG- 9 
THS494-2  Spain TG- 3  THS72314-07 China, Ningxia TG- 7  THS71534 China, Gansu TG- 9 
THS494-3  Spain TG- 3  THS72314-08 China, Ningxia TG- 7  THS71537 China, Gansu TG- 9 
THS494-4  Spain TG- 3  THS72316-06 China, Nei Monggol TG- 7  THS71540 China, Gansu TG- 9 
THS494-5  Spain TG- 3  THS72317-05 China, Nei Monggol TG- 7  THS72314-04 China, Ningxia TG- 9 
THS494-6  Spain TG- 3  THS72319 China, Nei Monggol TG- 7  THS72314-05 China, Ningxia TG- 9 
THS494-7  Spain TG- 3  THS770-2 China, Liaoning TG- 7  THS72314-06 China, Ningxia TG- 9 
OY-22  Italy TG- 3  THS72270 China, Xinjiang TG- 8  THS72315-01 China, Ningxia TG- 9 
THS41794  Turkey TG- 3  THS72273 China, Xinjiang TG- 8  THS72315-05 China, Ningxia TG- 9 
THS31678  Turkey TG- 3  THS72274 China, Xinjiang TG- 8  THS41885 China, Nei Monggol TG- 9 
THS496-1  Turkey TG- 3  THS72272 China, Xinjiang TG- 8  TUS118100 China, Nei Monggol TG- 9 
THS496-2  Turkey TG- 3  THS40621 China, Xinjiang TG- 8  TUS95951 China, Nei Monggol TG- 9 
OY-9  Turkey TG- 3  THS500-6 China, Xinjiang TG- 8  TI China, Nei Monggol TG- 9 
THS72275  China, Xinjiang TG- 3  THS501-2 China, Xinjiang TG- 8  THS72317-01 China, Nei Monggol TG- 9 
THS72276  China, Xinjiang TG- 3  THS43475 China, Xinjiang TG- 8  THS72317-02 China, Nei Monggol TG- 9 
THS40866  China, Xinjiang TG- 3  THS43480 China, Xinjiang TG- 8  THS72317-03 China, Nei Monggol TG- 9 
THS72277  China, Xinjiang TG- 3  THS43481 China, Xinjiang TG- 8  THS72317-04 China, Nei Monggol TG- 9 
THS72278  China, Xinjiang TG- 3  THS43483 China, Xinjiang TG- 8  THS72317-06 China, Nei Monggol TG- 9 
THS72279  China, Xinjiang TG- 3  THS44496 China, Xinjiang TG- 8  KUN0615911 China, Shaanxi TG- 9 
OY-4  clutivated in OY TG- 3  THS44497 China, Xinjiang TG- 8  THS42163 China, Shanxi TG- 9 
OY-5  clutivated in OY TG- 3  THS44498 China, Xinjiang TG- 8  THS32115 China, Hebei TG- 9 
OY-11  clutivated in OY TG- 3  THS44499 China, Xinjiang TG- 8  THS42161 China, Hebei TG- 9 
OY  clutivated in OY TG- 3  THS44500 China, Xinjiang TG- 8  THS42162 China, Hebei TG- 9 
OY  clutivated in OY TG- 3  THS44501 China, Xinjiang TG- 8  THS40393 China, Heilongjiang TG- 9 
OY  clutivated in OY TG- 3  THS44502 China, Xinjiang TG- 8  THS40392 China, Heilongjiang TG- 9 
THS35184  - TG- 3  THS44503 China, Xinjiang TG- 8  THS15811 China, Heilongjiang TG- 9 
THS40627  China, Xinjiang TG- 7  THS44504 China, Xinjiang TG- 8  THS41990 China, Liaoning TG- 9 
THS497-2  China, Xinjiang TG- 9  THS44505 China, Xinjiang TG- 8  THS770-1 China, Liaoning TG- 9 
THS31689  Turkey ADD  THS44506 China, Xinjiang TG- 8  KUN43222 China, Liaoning TG- 9 
THS497-1  China, Xinjiang ADD  THS44507 China, Xinjiang TG- 8  KUN43223 China, Liaoning TG- 9 
THS498-1  China, Xinjiang ADD  THS44508 China, Xinjiang TG- 8  OY-16 clutivated in OY TG- 9 
THS498-2  China, Xinjiang ADD  THS44509 China, Xinjiang TG- 8  OY clutivated in OY TG- 9 
THS498-3  China, Xinjiang ADD  THS44510 China, Xinjiang TG- 8  THS38110 - TG- 9 
THS498-4  China, Xinjiang ADD  THS44511 China, Xinjiang TG- 8  THS40619 China, Xinjiang ADD 
     THS44512 China, Xinjiang TG- 8  THS40622 China, Xinjiang ADD 
     THS44513 China, Xinjiang TG- 8  THS40624 China, Xinjiang ADD 
     THS44514 China, Xinjiang TG- 8  THS43476 China, Xinjiang ADD 
     THS44515 China, Xinjiang TG- 8  THS43479 China, Xinjiang ADD 
     THS44516 China, Xinjiang TG- 8  THS500-1 China, Xinjiang ADD 
     THS44517 China, Xinjiang TG- 8  THS500-2 China, Xinjiang ADD 
     THS44518 China, Xinjiang TG- 8  THS500-3 China, Xinjiang ADD 
     THS44519 China, Xinjiang TG- 8  THS501-1 China, Xinjiang ADD 
     THS44520 China, Xinjiang TG- 8  OY-21 clutivated in OY ADD 
 
The herbarium abbreviations of the vouchers meant Osaka University of Pharmaceutical Sciences 
(OY), Tsumura & Co. (THS), University of Tokyo (TI), and Tohoku University (TUS). 
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Table 3.2.  Variable sites and genotypes obtained from the nucleotide sequences of ITS, rbcL, matK 
and trnH−psbA. 
 
ITS 
(AB280738 = I-3) 
 
rbcL 
(AB012126 = R-2) 
 
matK 
(AB28071 = M-1) 
 
trnH – psbA 
(AB280745 = T-4) 
 site    site    site   Site 
 187 411-413   706 736   568-573   72 125 171 
I-1 T TGC  R-1 A T  M-1 CTTATT  T-1 C A T 
I-2 T CAA  R-2 G A  M-2 Deletion  T-2 C A G 
I-3 C TGC         T-3 T A T 
ADD Y YRM         T-4 C G T 
 
The variable sites were located on the sequence with the accession number. Gray backgrounds indicate 
nucleotide substitutions or a deletion compared with I-1, R-1, M-1, or T-1. IUPAC ambiguity symbols 
are adopted (Y = C + T, R = A + G, M = A + C). 
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Table 3.3.  Species identified by morphological characteristics and maternal species presumed by 
cpDNA information of the hybrids with the ADD of the total genotype. 
 
Species  Voucher Locality Genotype  Maternal 
identified by     species 
morphologic    ITS rbcL matK trnH presumed from 
characteristics    –psbA  cpDNA genotypes 
    
G. uralensis THS40619 China, Xinjiang ADD R-1 M-2 T-3 G. inflata 
 THS40622 China, Xinjiang ADD R-1 M-1 T-1 G. uralensis 
       or G. glabra 
       or G. inflata 
 THS40624 China, Xinjiang ADD R-1 M-2 T-3 G. inflata 
 THS43476 China, Xinjiang ADD R-1 M-1 T-3 G. glabra 
       or G. inflata 
 THS43479 China, Xinjiang ADD R-1 M-1 T-2 G. uralensis 
       or G. glabra 
 THS500-1 China, Xinjiang ADD R-2 M-1 T-4 G. uralensis 
 THS500-2 China, Xinjiang ADD R-2 M-1 T-4 G. uralensis 
 THS500-3 China, Xinjiang ADD R-2 M-1 T-4 G. uralensis 
 THS501-1 China, Xinjiang ADD R-2 M-2 T-3 G. uralensis  
       or G. inflata 
 OY-21 Cultivated in OY ADD R-2 M-1 T-1 G. uralensis 
 
G. glabra THS31689 Turkey ADD R-1 M-1 T-2 G. uralensis 
       or G. glabra 
 THS497-1 China, Xinjiang ADD R-2 M-1 T-4 G. uralensis 
 THS498-1 China, Xinjiang ADD R-1 M-2 T-3 G. inflata 
 THS498-2 China, Xinjiang ADD R-1 M-2 T-3 G. inflata 
 THS498-3 China, Xinjiang ADD R-1 M-2 T-3 G. inflata 
 THS498-4 China, Xinjiang ADD R-1 M-2 T-3 G. inflata 
 
G. inflata THS71521 China, Gansu ADD R-2 M-1 T-1 G. uralensis 
 
 
 
. 
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Licorice （甘草） 
 
   
G. uralensis                 G. glabra                 G. inflata 
 
Figure 3.1.  Crude drug of licorice and fruits of medicinal used Glycyrrhiza species. The clude drug 
name of licorice written in Chinese characters were indicated in parentheses. 
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Figure 3.2.  Total genotype (TG-1−TG-9 and ADD) consisted of the combination of the genotype (I-
1−I-3, ADD, R-1−R-2, M-1−M-2, and T-1−T-4) obtained from the ITS, rbcL, matK and 
trnH-psbA. Under the genotypes, the frequency of appearance of each species identified 
by aerial morphologic features is shown by each total genotype. Phylogenetic 
relationships among the total genotypes were described as the only most-parsimonious 
tree of eight steps long. The tree consistency index was 0.875. 
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Figure 3.3.  205 samples examined with the total genotype mapped by each province in China. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
Chapter 4    
 
Chemical properties of botanical raw materials identified by molecular makers 
 
Constituent properties of licorices derived from Glycyrrhiza uralensis,  
G. glabra, or G. inflata identified by molecular markers 
 
4.1  Introduction 
Licorice is one of the most useful herbs in traditional Chinese medicine and Japanese Kampo 
medicine. In the Chinese Pharmacopoeia, three species of Glycyrrhiza uralensis, G. glabra, and G. 
inflate are prescribed as licorice: (Chinese Pharmacopeia Commission, 2015c). In the Japanese 
Pharmacopoeia, two species of G. uralensis and G. glabra are prescribed (MHLW, 2016d). Constituent 
properties of licorices derived from the three species have been reported about eleven kinds of 
constituent contents (Yoneda et al., 1990; Yoneda et al., 1991), HPLC patterns (Shibano et al., 1996; 
Kitagawa et al., 1998), and species-specific constituents of glycycoumarin, glabridin, or licochalcone 
A (Shibata et al., 1978; Hatano et al., 1991; Hayashi et al., 2000). However, it was difficult to clarify 
differences of constituent properties among licorices derived from the three species because the 
accurate species identification of licorice was difficult from their morphological features of roots or 
rhizomes those were medicinal parts, and existences of hybrids among Glycyrrhiza species have been 
reported, too (Ashurmetov, 1996; Hayashi et al., 2003 and 2005). The method of species identification 
of licorice using four kinds of genetic markers; ITS on nuclear ribosomal DNA (nrDNA), rbcL gene, 
matK gene, and trnH–psbA intergenic region on chloroplast DNA (cpDNA) have been reported 
(Kondo et al., 2007b). This method would be able to detect the hybrid between G. uralensis and either 
G. glabra or G. inflata from the ITS sequence. 
In this study, to define the differences of constituent properties among the licorices derived from 
the three species, at first, original species of 117 licorices were identified by their nucleotide sequences 
of the four kinds of DNA regions reported by Kondo et al. (2007b). Secondly, contents of six kinds of 
main constituents of licorice that were glycyrrhizin, liquiritin, liquiritin apioside, isoliquiritin, 
isoliquiritin apioside, and liquiritigenin, and three kinds of the species-specific constituents that were 
glycycoumarin, glabridin, and licochalcone A were measured in the 117 licorices. Consequently, the 
constituent properties by the licorice derived from the three Glycyrrhiza species used medicinally were 
reconfirmed. 
 
4.2  Materials and methods 
Materials 
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Vouchers and localities of 117 licorices were listed (Table 4.1). The vouchers were deposited in 
the herbarium of Tsumura & Co. in Japan. 
DNA sequencing and species identification 
The methods of the DNA sequencings of ITS, rbcL, matK, and trnH–psbA, and of the species 
identification of licorices were followed the methods of the chapter 3 in this thesis or Kondo et al. 
(2007b).  
Chemical Analysis 
The powders of licorice (0.05 g) were extracted with 80% methanol (25 ml) under ultra-
sonication for 30 min. This operation was repeated and scaled up to 50 ml. The 20 ml of this extract 
was submitted to HPLC analysis. HPLC equipped with a LC-10 system (Shimadzu) using a TSK gel 
ODS-80TS column (250 x 4.6 mm) was used. The solvents were 0.05M AcONH4 (pH 3.6) (A) and 
CH3CN (B). A linear gradient of 100% (A) and 0% (B) changing over 60min. to 0% (A) and 100% 
(B) was used. The flow rate was 1.0 ml/min. The effluent from the column was monitored at from 200 
nm to 400 nm. 
Statistical Analysis 
Significant differences and a principal component analysis for the constituent contents were 
calculated by the Excel statistics 2002 for windows software (Social Survey Research Information Co., 
Ltd., 2002). 
 
4.3  Results 
Species identification of 117 licorices based on the four kinds of molecular markers 
Six kinds of the genotypes (TG-3, TG-5, TG-7, TG-8, TG-9, and ADD, chapter 3 in this thesis or 
Kondo et al., 2007b) were recognized by the DNA sequencings of ITS, rbcL, matK, and trnH–psbA 
for the 117 licorices (Table 4.1). Seventeen licorices located in Russia, France, Holland, Germany, 
Iran, Afghanistan, and Xinjiang in China had the TG-3 genotype and were identified as G. glabra. 
Eight licorices in Xinjiang and Gansu in China had the TG-5 genotype and were identified as G. inflata. 
Eighty seven licorices in Russia and a large north area from Jilin to Xinjiang province in China had 
the tg7 (n = 14), tg8 (n = 19), and tg9 (n = 54) genotypes and were identified as G. uralensis. Five 
licorices in Xinjiang and Gansu in China had the ADD genotype and were identified as hybrids 
between G. uralensis and either G. glabra or G. inflata. 
Six kinds of main constituent contents 
The contents of the six kinds of main constituents that were glycyrrhizin, liquiritin, liquiritin 
apioside, isoliquiritin, isoliquiritin apioside, and liquiritigenin in the 117 licorices examined were 
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indicated in Table 4.1 and Fig. 4.1. Comparing mean contents of the six main constituents by G. 
uralensis, G. glabra, or G. inflata identified from the genotypes, there was no significant difference 
among the three species in the contents of glycyrrhizin, liquiritin apioside, or isoliquiritin apioside. 
While, the mean contents of liquiritin, isoliquiritin, and liquilitigenin in G. uralensis were significantly 
higher than those of G. glabra or G. inflata (Fig. 4.1).  
In the result of a principal component analysis for the six main constituent contents, the licorices 
derived from G. glabra and G. inflata were located together on the third quadrant of the scatter diagram 
mainly, while G. uralensis were scattered on all the quadrants (Fig. 4.2). It meant that the content 
property of the six main constituents of G. glabra resembles to G. inflata. On the other hand, the 
content property of the six main constituents of G. uralensis were distinguishable from G. glabra or 
G. inflata, and was characterized by a wider content variation than that of G. glabra or G. inflata. 
In G. uralensis, the three kinds of genotypes (TG-7, TG-8, TG-9) were recognized as intra-
specific variations. There is no difference of content properties among licorices having the three 
genotypes on the scatter diagram of the principal component analysis. Additionally, five licorices 
presumed as hybrids with the ADD genotype located at the intermediate area in the distributions of 
the three species on the scatter diagram (Fig. 4.2). 
Species-specific constituents of licorice 
Glycycoumarin, glabridin, or licochalcone A have been reported as the species-specific 
constituents of G. uralensis, G. glabra, or G. inflata respectively. Their constituent contents in the 117 
licorices examined were indicated in Table 4.1 and Fig. 4.1. The detection frequencies of the three 
kinds of the species-specific constituents by the three species and hybrid identified from the genotypes 
were indicated in Table 4.2. In G. glabra (n = 17), 88% (n = 15) had glabridin and 12% (n = 2) had no 
species-specific constituents. In G. inflata (n = 8), 88% (n = 7) had licochalcone A and 12% (n = 1) 
had no species-specific constituent. In G. uralensis (n = 87), 95% (n = 83) had glycycoumarin and 5% 
(n = 4) had no species- specific constituent. In hybrids between G. uralensis and either G. glabra or 
G. inflata (n = 5), 40% (n = 2) had glycycoumarin and 60% (n = 3) had licochalcone A. From this 
result, it was reconfirmed that glabridin, licochalcon A, or glycycoumarin were species-specific 
constituents of G. glabra, G. inflata, or G. uralensis respectively because each constituent was 
recognized in only G. glabra, G. inflata, or G. uralensis identified by the genotype, respectively. 
Meanwhile, in the hybrids identified by their genotypes, only one kind of species-specific 
constituent was detected from an individual plant but not two or more kinds of the species-specific 
constituents derived from their both parents of hybridization (Table 4.1). 
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4.4  Discussion 
Species selection of licorice for the medicinal use 
From the comparisons of the main and species-specific constituent contents of 117 licorices 
identified species using the molecular markers, it was revealed that the constituent property of G. 
uralensis was distinguishable from of G. glabra or G. inflata. The mean contents of liquiritin, 
isoliquiritin, and liquilitigenin in G. uralensis were significantly higher than those of G. glabra or G. 
inflata. Especially, liquiritin in G. uralensis had more than 1 % higher content than that of G. glabra 
or G. inflata. 
 Therefore, species should be selected according to the medicinal purpose however every G. 
uralensis, G. glabra, and G. inflata could be used as the crude drug licorice in the Chines 
pharmacopeia. For example, isoliquiritin had inhibitory effects on aldose reductase activity and 
granuloma angiogenesis (Aida et al., 1989; Kobayashi et al., 1995). Hence, licorice used for Byakko-
ka-ninjin-to or Saiko-keishi-kankyo-to in the Japanese Kampo medicines that were often used as a 
diabetic medicine (Hujihira, 1982) should be selected under consideration of the amount of 
isoliquiritin in their prescriptions. Additionally, an antitussive effect of liquiritin apioside, 
liquiritigenin, and liquiritin, and a week estrogen-like activity of liquiritigenin have been reported 
(Kamei et al., 2005; Nomura et al., 2002). 
Species identification of the species-specific constituents 
Species identification of the three species-specific constituents of glycycoumarin, glabridin, or 
licochalcone A would be effective because those results were the almost same as the results of the 
species identification by the genotypes. However, there was no detection of the three species-specific 
constituents from 6% (= 7/117) of licorices examined. Additionally, the hybrids would not be detected 
from the species-specific constituents because the five putative hybrids with the ADD genotype 
observed in this study had only one kind of the species-specific constituent. It was not known exactly 
why the putative hybrid had only one kinds of the species-specific constituent and should be 
researched in detail. 
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Table 4.1.  Vouchers, locations, species identified by the genotypes, the six kinds of main constituent 
contents of licorice, and the three kinds of species-specific constituent contents of 117 
licorices examined. 
Voucher Locality 
    Geno- 
    type 
Species 
    by 
genotype 
Main constituent contents (%)   
Species-specific  
  constituent contents (%) 
   Glycyr- 
rhizin 
Liquiri- 
tin 
Liquiritin 
apioside 
Iso- 
liquiritin 
Iso- 
liquiritin  
apioside 
Liquiriti- 
genin 
 
Glycy- 
coumarin 
Glabridin 
Lico- 
chalconeA 
THS60130 Russia TG-3 G. glabla 5.860  0.112  2.131  n.d. 0.838  n.d.  n.d. 0.273  n.d. 
THS61104 Russia TG-3 G. glabla 3.787  0.097  1.217  n.d. 0.515  n.d.  n.d. 0.136  n.d. 
THS61121 Russia TG-3 G. glabla 7.007  0.232  1.612  n.d. 0.625  0.043   n.d. 0.045  n.d. 
THS66496 Spain TG-3 G. glabla 2.787  0.107  2.743  n.d. 1.021  0.021   n.d. 0.247  n.d. 
THS66495 France TG-3 G. glabla 2.666  0.078  2.674  n.d. 0.213  n.d.  n.d. 0.102  n.d. 
THS66497 Holland TG-3 G. glabla 4.206  0.144  1.802  n.d. 0.699  0.023   n.d. 0.239  n.d. 
THS66219 Germany TG-3 G. glabla 1.875  0.134  0.723  0.047  0.240  0.022   n.d. 0.055  n.d. 
THS66221 Germany TG-3 G. glabla 4.842  0.106  1.612  n.d. 0.616  n.d.  n.d. 0.026  n.d. 
THS54514 Iran TG-3 G. glabla 2.301  0.035  0.904  n.d. 0.339  n.d.  n.d. 0.056  n.d. 
THS64261 Iran TG-3 G. glabla 3.481  0.008  1.373  n.d. 0.455  0.010   n.d. n.d. n.d. 
THS60101 Afghanistan TG-3 G. glabla 5.384  0.096  1.683  n.d. 0.726  n.d.  n.d. 0.345  n.d. 
THS71515 China, Xinjiang TG-3 G. glabla 0.991  0.223  0.598  0.030  0.160  0.022   n.d. n.d. n.d. 
THS72275 China, Xinjiang TG-3 G. glabla 2.275  0.049  0.937  n.d. 0.383  0.070   n.d. 0.159  n.d. 
THS72276 China, Xinjiang TG-3 G. glabla 3.080  0.352  1.784  0.077  0.519  n.d.  n.d. 0.157  n.d. 
THS72277 China, Xinjiang TG-3 G. glabla 2.984  0.308  1.859  0.070  0.629  0.023   n.d. 0.099  n.d. 
THS72278 China, Xinjiang TG-3 G. glabla 1.766  0.148  0.845  n.d. 0.293  n.d.  n.d. 0.207  n.d. 
THS72279 China, Xinjiang TG-3 G. glabla 4.867  0.660  2.759  0.165  0.813  0.045   n.d. 0.259  n.d. 
THS40620 China, Xinjiang TG-5 G. inflata 2.401  0.363  0.806  0.068  0.280  0.038   n.d. n.d. 0.686  
THS40630 China, Xinjiang TG-5 G. inflata 2.540  0.084  0.841  0.011  0.321  n.d.  n.d. n.d. 1.820  
THS60203 China, Xinjiang TG-5 G. inflata 1.129  0.264  0.843  0.038  0.208  0.026   n.d. n.d. n.d. 
THS72281 China, Xinjiang TG-5 G. inflata 5.380  0.385  2.291  0.059  0.855  n.d.  n.d. n.d. 0.634  
THS72282 China, Xinjiang TG-5 G. inflata 3.771  0.195  1.663  0.026  0.600  0.078   n.d. n.d. 0.762  
THS72283 China, Xinjiang TG-5 G. inflata 5.320  0.465  2.445  0.065  0.866  n.d.  n.d. n.d. 0.659  
THS72284 China, Xinjiang TG-5 G. inflata 4.143  0.296  1.947  0.037  0.648  n.d.  n.d. n.d. 1.037  
THS71518 China, Gansu TG-5 G. inflata 1.453  0.119  0.959  0.020  0.297  0.021   n.d. n.d. 0.338  
THS58482 Russia TG-7 G. uralensis 6.178  2.984  2.975  0.799  1.219  0.084   n.d. n.d. n.d. 
THS40627 China, Xinjiang TG-7 G. uralensis 0.850  0.282  0.557  0.050  0.157  0.008   n.d. n.d. n.d. 
THS64165 China, Gansu TG-7 G. uralensis 6.721  3.110  1.069  0.675  0.347  0.134   0.139  n.d. n.d. 
THS72299 China, Gansu TG-7 G. uralensis 2.744  1.876  1.016  0.330  0.315  0.115   0.139  n.d. n.d. 
THS58610 China, Ningxia TG-7 G. uralensis 1.847  0.449  1.859  0.069  0.604  0.061   0.070  n.d. n.d. 
THS72303 China, Ningxia TG-7 G. uralensis 3.008  2.153  0.390  0.444  0.094  0.108   0.031  n.d. n.d. 
THS72305 China, Ningxia TG-7 G. uralensis 2.658  0.659  1.418  0.136  0.607  0.029   0.078  n.d. n.d. 
THS58144 China, Shaanxi TG-7 G. uralensis 4.519  1.371  1.646  0.261  0.704  0.068   0.033  n.d. n.d. 
THS58600 China, Shaanxi TG-7 G. uralensis 2.475  1.773  0.699  0.329  0.160  0.138   0.055  n.d. n.d. 
THS59991 China, Shaanxi TG-7 G. uralensis 1.966  1.303  1.118  0.184  0.277  0.063   0.101  n.d. n.d. 
THS72285 China, Nei Monggol TG-7 G. uralensis 3.364  1.612  0.694  0.299  0.179  0.164   n.d. n.d. n.d. 
THS72286 China, Nei Monggol TG-7 G. uralensis 6.183  4.061  2.407  0.753  0.747  0.279   0.188  n.d. n.d. 
THS42161 China, Hebei TG-7 G. uralensis 2.230  1.432  1.399  0.233  0.407  0.050   0.143  n.d. n.d. 
THS72290 China, Liaoning TG-7 G. uralensis 2.010  1.593  1.331  0.302  0.416  0.072   0.025  n.d. n.d. 
THS40621 China, Xinjiang TG-8 G. uralensis 3.030  1.002  0.994  0.252  0.248  0.130   0.049  n.d. n.d. 
THS40629 China, Xinjiang TG-8 G. uralensis 2.222  1.146  1.162  0.216  0.286  0.054   0.055  n.d. n.d. 
THS56597 China, Xinjiang TG-8 G. uralensis 1.996  0.076  0.857  0.013  0.281  0.070   n.d. n.d. n.d. 
THS72270 China, Xinjiang TG-8 G. uralensis 2.628  0.477  0.713  0.151  0.213  0.026   0.045  n.d. n.d. 
THS72271 China, Xinjiang TG-8 G. uralensis 2.762  0.843  0.622  0.223  0.177  0.066   0.016  n.d. n.d. 
THS72273 China, Xinjiang TG-8 G. uralensis 2.057  0.873  0.805  0.154  0.215  0.087   0.015  n.d. n.d. 
THS72274 China, Xinjiang TG-8 G. uralensis 3.228  1.327  0.894  0.228  0.197  0.065   0.018  n.d. n.d. 
THS61198 China, Gansu TG-8 G. uralensis 2.692  0.989  1.605  0.182  0.435  0.085   0.086  n.d. n.d. 
THS71543 China, Gansu TG-8 G. uralensis 1.058  0.285  0.742  0.039  0.209  0.013   0.038  n.d. n.d. 
THS72297 China, Gansu TG-8 G. uralensis 3.165  2.070  0.738  0.492  0.200  0.285   0.130  n.d. n.d. 
THS72302 China, Ningxia TG-8 G. uralensis 4.085  1.512  1.424  0.307  0.585  0.047   0.074  n.d. n.d. 
THS42506 China, Nei Monggol TG-8 G. uralensis 0.595  0.139  0.425  0.023  0.115  0.011   0.054  n.d. n.d. 
THS42508 China, Nei Monggol TG-8 G. uralensis 1.130  0.635  0.384  0.136  0.120  0.099   0.073  n.d. n.d. 
THS58985 China, Nei Monggol TG-8 G. uralensis 3.854  2.727  0.856  0.357  0.251  0.066   0.171  n.d. n.d. 
THS59002 China, Nei Monggol TG-8 G. uralensis 4.514  2.060  4.216  0.329  1.260  0.120   0.064  n.d. n.d. 
THS72295 China, Nei Monggol TG-8 G. uralensis 1.126  0.159  0.861  0.032  0.223  0.042   0.054  n.d. n.d. 
THS31537 China, Hebei TG-8 G. uralensis 5.578  4.022  1.557  0.750  0.401  0.049   0.121  n.d. n.d. 
THS61625 China, Jilin TG-8 G. uralensis 4.650  2.419  1.141  0.460  0.335  0.390   0.160  n.d. n.d. 
THS41989 China, Liaoning TG-8 G. uralensis 1.924  1.333  0.585  0.312  0.158  0.074   0.031  n.d. n.d. 
THS72304 China, Qinghai TG-9 G. uralensis 3.950  3.157  1.431  0.474  0.362  0.014   0.103  n.d. n.d. 
THS58707 China, Gansu TG-9 G. uralensis 2.110  1.827  1.199  0.224  0.280  0.096   0.021  n.d. n.d. 
THS61197 China, Gansu TG-9 G. uralensis 4.739  3.269  1.506  0.638  0.387  0.081   0.235  n.d. n.d. 
THS64188 China, Gansu TG-9 G. uralensis 4.974  1.489  1.112  0.371  0.405  0.175   0.205  n.d. n.d. 
THS71524 China, Gansu TG-9 G. uralensis 2.566  1.434  0.611  0.242  0.159  0.012   0.079  n.d. n.d. 
THS71528 China, Gansu TG-9 G. uralensis 2.319  1.229  0.400  0.160  0.101  0.007   0.101  n.d. n.d. 
THS71531 China, Gansu TG-9 G. uralensis 2.434  1.046  0.348  0.208  0.117  0.019   0.062  n.d. n.d. 
THS71534 China, Gansu TG-9 G. uralensis 2.741  1.425  0.722  0.221  0.232  0.028   0.066  n.d. n.d. 
THS71537 China, Gansu TG-9 G. uralensis 3.083  0.912  0.821  0.139  0.301  0.064   0.083  n.d. n.d. 
THS71540 China, Gansu TG-9 G. uralensis 2.686  1.051  0.674  0.196  0.218  0.053   0.052  n.d. n.d. 
THS72300 China, Gansu TG-9 G. uralensis 3.405  1.208  1.471  0.203  0.411  0.024   0.073  n.d. n.d. 
THS72306 China, Ningxia TG-9 G. uralensis 4.421  2.666  2.677  0.395  0.782  0.064   0.092  n.d. n.d. 
THS58143 China, Shaanxi TG-9 G. uralensis 2.090  0.302  1.133  0.081  0.407  0.073   0.039  n.d. n.d. 
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Table 4.1. (continued) 
       
Voucher Locality 
 Geno- 
   type 
Species 
      by  
genotype 
Contents of the six main constituents  
of licorice (%) 
 
Contents of the species-specific 
constituens (%) 
   Glycyr- 
rhizin 
Liquiri- 
tin 
Liquiritin 
apioside 
Iso- 
liquiritin 
Iso- 
liquiritin  
apioside 
Liquiriti- 
genin 
 
Glycy- 
coumarin 
Glabridin 
Lico- 
chalcone
A 
THS58171 China, Shaanxi TG-9 G. uralensis 3.435  0.810  2.156  0.173  0.800  0.046   0.100  n.d. n.d. 
THS66460 China, Shanxi TG-9 G. uralensis 2.810  1.996  1.586  0.342  0.483  0.051   0.079  n.d. n.d. 
THS42504 China, Nei Monggol TG-9 G. uralensis 1.187  0.561  0.394  0.104  0.119  0.016   0.053  n.d. n.d. 
THS58601 China, Nei Monggol TG-9 G. uralensis 7.671  3.900  1.910  0.834  0.531  0.136   0.057  n.d. n.d. 
THS58605 China, Nei Monggol TG-9 G. uralensis 0.964  0.264  0.443  0.043  0.135  0.022   0.031  n.d. n.d. 
THS58743 China, Nei Monggol TG-9 G. uralensis 4.147  1.441  1.546  0.268  0.518  0.480   0.087  n.d. n.d. 
THS58745 China, Nei Monggol TG-9 G. uralensis 3.700  1.801  2.295  0.241  0.728  0.030   0.098  n.d. n.d. 
THS58747 China, Nei Monggol TG-9 G. uralensis 5.524  2.123  1.637  0.406  0.627  0.083   0.193  n.d. n.d. 
THS58748 China, Nei Monggol TG-9 G. uralensis 3.303  0.875  1.392  0.127  0.504  0.058   0.150  n.d. n.d. 
THS58966 China, Nei Monggol TG-9 G. uralensis 5.244  3.236  1.824  0.568  0.619  0.057   0.094  n.d. n.d. 
THS58967 China, Nei Monggol TG-9 G. uralensis 2.742  1.863  0.675  0.281  0.214  0.052   0.055  n.d. n.d. 
THS58968 China, Nei Monggol TG-9 G. uralensis 4.915  3.719  0.895  0.666  0.240  0.050   0.083  n.d. n.d. 
THS58986 China, Nei Monggol TG-9 G. uralensis 3.281  2.532  1.414  0.446  0.401  0.052   0.088  n.d. n.d. 
THS58987 China, Nei Monggol TG-9 G. uralensis 5.510  2.934  2.669  0.475  0.916  0.092   0.118  n.d. n.d. 
THS60967 China, Nei Monggol TG-9 G. uralensis 4.033  1.809  2.361  0.340  0.701  0.101   0.228  n.d. n.d. 
THS64185 China, Nei Monggol TG-9 G. uralensis 3.533  1.832  0.748  0.342  0.250  0.067   0.145  n.d. n.d. 
THS65279 China, Nei Monggol TG-9 G. uralensis 3.260  2.086  1.630  0.341  0.506  0.196   0.111  n.d. n.d. 
THS65898 China, Nei Monggol TG-9 G. uralensis 5.474  4.356  1.495  1.256  0.406  0.407   0.080  n.d. n.d. 
THS72287 China, Nei Monggol TG-9 G. uralensis 4.523  3.281  1.477  0.401  0.438  0.103   0.215  n.d. n.d. 
THS72288 China, Nei Monggol TG-9 G. uralensis 0.259  0.136  0.502  0.015  0.099  0.011   0.085  n.d. n.d. 
THS72291 China, Nei Monggol TG-9 G. uralensis 3.181  3.458  2.431  0.404  0.617  0.057   0.137  n.d. n.d. 
THS72292 China, Nei Monggol TG-9 G. uralensis 5.858  1.048  1.287  0.248  0.673  0.156   0.053  n.d. n.d. 
THS72293 China, Nei Monggol TG-9 G. uralensis 4.228  1.696  0.868  0.284  0.272  0.031   0.078  n.d. n.d. 
THS72294 China, Nei Monggol TG-9 G. uralensis 4.439  3.132  2.441  0.524  0.673  0.115   0.158  n.d. n.d. 
THS72296 China, Nei Monggol TG-9 G. uralensis 3.395  1.204  1.225  0.264  0.505  0.129   0.120  n.d. n.d. 
THS72307 China, Nei Monggol TG-9 G. uralensis 7.009  3.234  1.827  0.764  0.637  0.637   0.044  n.d. n.d. 
THS64732 China, Hebei TG-9 G. uralensis 8.310  3.935  3.571  0.836  1.470  0.284   0.165  n.d. n.d. 
THS64733 China, Hebei TG-9 G. uralensis 3.878  1.262  1.140  0.265  0.561  0.155   0.045  n.d. n.d. 
THS64864 China, Hebei TG-9 G. uralensis 2.962  2.457  0.783  0.467  0.202  0.210   0.077  n.d. n.d. 
THS65441 China, Hebei TG-9 G. uralensis 3.429  1.388  1.110  0.259  0.358  0.148   0.157  n.d. n.d. 
THS72301 China, Hebei TG-9 G. uralensis 3.166  1.625  1.083  0.233  0.253  0.054   0.079  n.d. n.d. 
THS72308 China, Hebei TG-9 G. uralensis 1.927  1.811  0.560  0.277  0.125  0.041   0.057  n.d. n.d. 
THS41990 China, Liaoning TG-9 G. uralensis 3.267  1.846  0.830  0.378  0.242  0.085   0.092  n.d. n.d. 
THS58141 China, Liaoning TG-9 G. uralensis 3.381  1.011  1.356  0.211  0.451  0.161   0.137  n.d. n.d. 
THS72298 China, Heilongjiang TG-9 G. uralensis 3.304  1.842  2.007  0.289  0.552  0.101   0.209  n.d. n.d. 
THS62089 China, Jilin TG-9 G. uralensis 2.749  0.529  1.863  0.108  0.675  0.101   0.131  n.d. n.d. 
THS66783 China, Jilin TG-9 G. uralensis 2.945  1.486  1.077  0.307  0.249  0.152   0.066  n.d. n.d. 
THS72309 China, Jilin TG-9 G. uralensis 3.482  2.183  2.434  0.253  0.731  0.063   0.061  n.d. n.d. 
THS58598 China, Liaoning TG-9 G. uralensis 3.396  1.932  0.578  0.451  0.153  0.469   0.080  n.d. n.d. 
THS65901 China, Liaoning TG-9 G. uralensis 6.165  2.892  1.218  0.892  0.392  0.609   0.095  n.d. n.d. 
THS40622 China, Xinjiang ADD Hybrid 1.517  0.741  0.816  0.115  0.170  0.027   0.043  n.d. n.d. 
THS40624 China, Xinjiang ADD Hybrid 3.741  0.538  0.459  0.172  0.215  0.076   0.048  n.d. n.d. 
THS40626 China, Xinjiang ADD Hybrid 1.656  0.318  0.360  0.074  0.120  0.051   n.d. n.d. 0.067  
THS40628 China, Xinjiang ADD Hybrid 2.352  0.232  0.968  0.042  0.374  n.d.  n.d. n.d. 0.813  
THS71521 China, Gansu ADD Hybrid 1.977  0.550  0.920  0.042  0.234  0.025   n.d. n.d. 0.361  
 
The voucher abbreviation means Tsumura & Co. (THS). “n. d.” means no detected of the constituent 
contents.  
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Table 4.2.  Detection frequencies of the three kinds of species-specific constituents by species 
identified from the genotypes for the 117 licorices examined. 
 
‘n. d.’ means no detected of the three species-specific constituents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genotype      Species identified 
               from genotype 
 Detection frequency of species specific constituents 
 Glycycoumarin Glabridin Licochalcone A n. d. 
TG-3         G. glabra   n = 17  0 15 (88 %) 0 2 (12 %) 
TG-5         G. inflata   n = 8  0 0 7 (88 %) 1 (12 %) 
TG-7, 8, 9     G. uralensis n = 87  83 (95 %) 0 0 4 ( 5 %) 
ADD         Hybrid     n = 5   2 (40 %) 0 3 (60 %) 0 
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Figure 4.1.  Contents of the six kinds of main constituents by G. uralensis (n = 87), G. glabra (n = 
17) and G. inflata (n = 8). Values indicated means ± S.D. ** P <0 .01 vs. G. uralensis. 
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Figure 4.2.  Scatter diagram of principal component analysis for the six kinds of the main 
constituents of Licorice derived from G. uralensis (n = 87), G. glabra (n = 17), G. 
inflata (n = 8) and Hybrids (n = 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
Chapter 5     
 
Historical study of an important crude drug using molecular markers 
 
Identification of the licorice root stored in Shosoin (正倉院, written in Chinese character) based on 
the sequences of internal transcribed spacer (ITS) on nuclear ribosomal DNA and the 
chemotaxonomic consideration 
 
5.1  Introduction 
Licorice stored in Shosoin (coded ML-44, N-99, Fig. 5.1) since 756AD is a national treasure. It 
was investigated morphologically at the first scientific investigation of Shosoin-medicaments (1948-
1949; Fujita et al., 1955), and was assigned to Glycyrrhiza glabra var. glandulifera Waldet & Kit. The 
assignment was according to the comparative microscopic observation of the tissue section of a 
specimen named Fukushu-licorice ( 福 州 甘 草 , written in Chinese character) stored in the 
Pharmaceutical institute, University of Tokyo. 
Licorice has well been known since ancient times in the East and West as a herb drug and a 
sweetening. According to the Shang-Han-Lun (傷寒論 , written in Chinese character), the oldest 
medical book written in the 1st century during Tang Dynasty, licorice was involved in 80% of the 113 
prescriptions cited there in. Among 60 kinds of medicaments stored in Shosoin, licorice (recorded 
with the quantity of 214 kg at the time of dedication, 756AD) was lost rapidly and only 10 kg remained 
after 100 years, indicating the high demand of this drug. 
The original licorice plants, Glycyrrhiza spp. in Leguminosae, are widely distributed over the 
Eurasian continent. They occur in eastern Mongolia, northeastern and northwestern China including 
Xinjiang province, central Asian countries, Afghanistan, Pakistan, Iran, Iraq, Turkey, Southern part 
of Russia, and even in Italy and Spain, but not in Japan.  
Therefore, Shosoin-licorice is apparently an imported material. The following species are the 
original licorice plants. Glycyrrhiza uralensis Fischer: northeastern China, far eastern Russia. G. 
glabra, L. var. typica, Reg. & Herd.: Spain, Italy. G. glabra, L. var. violacea Boiss: Turkey, Iran. G. 
glabra L. var. glandulifera Waldet & Kit: China, Russia, Central Asia. G. inflata Batalin: Xinjiang. 
G. enuricarpa, P. C. Li (= G. korshinskyi Grigori = G. uralensis x G. inflata): Xinjiang, Russia, Central 
Asia. G. aspera Pallas: Xinjiang. G. echinata L. and G. pallidiflora Maxim. are not in use for medical 
purpose. 
The botanical classification of licorice has been mostly according to the morphological 
observation of the aerial parts of Glycyrrhiza plants. The macro- and microscopic examination of the 
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roots is not so effective for the classification. Therefore, the morphological evaluation of licorice 
without aerial parts as a drug material is rather difficult. 
To get the more reliable identification of Shosoin-licorice, genetic analyses were applied to this 
problem. Previously, Kondo et al. (2007a) attempted several methods to determine the genetic 
identification of licorice species using ITS sequence on nuclear ribosomal DNA (nrDNA), the cording 
region of rbcL and matK genes, and trnH–psbA intergenic region on chloroplast DNA (cpDNA). 
Therefore, in this study, the sequencing above the DNA regions of the Shosoin- licorice were 
attempted. In the preliminary analyses, only the partial ITS fragment of the Shosoin-licorice could be 
amplified. The other molecular markers on cpDNA could not be amplified in the Shosoin-licorice due 
to the aging effect. 
Recently, the chemical principles of licorice extensively have been able to characterize. Apart 
from the well-established main saponin, glycyrrhizin, and its aglycone, glycyrrhetinic acid, a number 
of flavonoid compounds have been isolated and structurally established (Shibata et al., 1978; Nomura 
et al., 1998). The presence of some of these compounds was species-specific, so those could be applied 
to the chemotaxonomic survey and the species identification of licorice. 
As an appendix of the first investigation program of Shosoin-medicaments, one of the present 
authors performed HPLC analysis of Shosoin-licorice (ML-44, N-99) to identify its characteristic 
species-specific flavonoid constituents (Shibata, 1991). However, the result of HPLC was not so 
satisfactory, since the species-specific flavonoids in Shosoin-licorice were missing during the storage 
of more than 1250 years. 
In the present study as an appendix of the second scientific investigation of Shosoin-medicaments 
(1994-1995), the characteristic difference was researched between the Shosoin-licorice and the three 
representative species of licorice (G. uralensis, G. glabra, and G. inflata) in the ratio of occurrence of 
some common flavonoids (liquiritin, isoliquiritin, their apiosides and liquiritigenin). Furthermore, 
their characteristically differences were analyzed in a principal component analysis based on the above 
main flavonoids. This could be adoptable for the species identification of licorice roots. 
 
5.2  Materials and methods 
Genetic analysis 
Total DNA of the Shosoin-licorice (ML-44, N99) was extracted by using DNAeasy® Plant Mini 
Kit (QIAGEN) from the dried roots of the Shosoin-licorice. The partial DNA fragment of ITS (379 
bp) was amplified by polymerase chain reaction (Fig. 5.2). The amplifying primers for the ITS were 
as follows.  
Forward primers: GCC ACG CAC TGT GTT CTC TCC T.  
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Reverse primers: GCA ATG CTC ACG GGA AGC CAA CA. 
The composition of the reaction solution was 10 x Gene Tad Buffer (Nippon Gene) 5 µｌ, 2.5 mM 
dNTP mix (Nippon Gene) 4 µｌ, forward Primer (10 pmol/ml) 2.5 µｌ, reverse primer (10 pmol/ml) 2.5 
µｌ, Gene Taq (Nippon Gene) 0.25 µl, DMSO 5 µl, D.D.W. 25.75 µl, template DNA 5 µl. For the PCR 
cycle, the step-down method was applied (Kawakami et al., 1999). 
The amplified fragments were purified using the GFXTM PCR DNA and Gel Band Purification 
Kit (Amersham Biotech). The purified PCR products were sequenced by using the Big Dye Terminator 
Cycle Sequencing Kit ver. 2.0 and Model 3100 automated sequencer (Applied Bio Systems), 
following the manufacturer’s instructions. For DNA sequencing, the same primers used for the ITS 
fragment amplification were used as the sequencing primers. 
Chemical analysis 
The six kinds of main constituent contents of licorice that were glycyrrhizin, liquiritin, liquiritin 
apioside, isoliquiritin, isoliquiritin apioside, and liquiritigenin, and the three kinds of the species-
specific constituents that were glycycoumarin, glabridin, and licochalcone A in the Shosoin-licorice  
were measured by following methods. 500 mg of the Shosoin-licorice was used for extracting with 
80% methanol (25 ml) under ultra-sonication for 30 min. This operation was repeated and scaled up 
to 50 ml. I submitted 20 µl of this elution to HPLC analysis. HPLC was equipped with an LC-10 
system (Shimadzu Co., Ltd.) using a TSK gel ODS-80Ts column (250 x 4.6 mm). The solvents were 
A (0.05 M AcONH4 (pH 3.6)) and B (CH3CN). A linear gradient of A (100%) and B (0%) changing 
over 60 min to A (0%) and B (100%) was used. The flow rate was 1.0 ml/min. The effluent from the 
column at from 200 nm to 400 nm was monitored. 
In a principal component analysis based on the six main constituent contents using Excel 
Statistics 97 for Windows (Social Survey Research Information Co., Ltd. 2002), the constituent 
property of the Shosoin-licorice was compared with the species-specific constituent properties defined 
by the same research for the 117 of licorice (the chapter 4 in this thesis or Kondo et al., 2007a). 
 
5.3  Results 
ITS sequence of the Shosoin-licorice 
The partial ITS of the Shosoin-licorice stored since 756AD was amplified and sequenced (Fig. 
5.3). The previous study found that G. glabra and G. inflata showed nucleotides T at the site 1 (187th) 
and CAA at the site 2 (411-413th), while G. uralensis gave nucleotide C at the site 1 and TGC at the 
site 2 in ITS on nrDNA (the chapter 3 in this thesis or Kondo et al., 2007b). The ITS sequence of the 
Shosoin-licorice had the same nucleotides C at the site 1 and TGC at site 2 as that of G. uralensis (Fig. 
5.3). 
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Constituent contents of the Shosoin-licorice 
The contents of six principal constituents that were glycyrrhizin, liquiritin, liquiritin apioside, 
isoliquiritin, isoliquiritin apioside, liquiritigenin) of G. uralensis, G. glabra and G. inflata are tabulated 
in comparison with those of the Shosoin-licorice (Table 5.2). None of the species-specific flavonoids; 
glycycoumarin (G. uralensis), glabridin (G. glabra), and licochalcone A (G. inflata)) was detectable 
in the Shosoin-licorice probably due to aging destruction. 
Scatter diagram of the principal component analysis for the six main constituent contents of 
licorices identified from genotype of nrDNA (n = 117) and the Shosoin-licorice was illustrated in Fig. 
5.4. The Shosoin-licorice gave a spot in the region of G. uralensis. This result suggests that the 
constituent prosperity of the Shosoin-licorice resembled to of G. uralensis.  
 
5.4  Conclusion 
Based on the genetic and chemotaxonomic analyses, the botanical origin of Shosoin-licorice (ML-
44, N-99) was identified as the root of Glycyrrhiza uralensis Fischer. 
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Table 5.1.  The six principal constituent contents and the three species-specific constituent contents 
of the Shosoin-licorice and the three species of Glycyrrhiza identified from the genetic 
analyses of nrDNA and cpDNA. The data of three species referred in the chapter 4 in this 
thesis or Kondo et al. (2007a). 
 
 main constituent contents (%) 
 Species-specific constituent 
contents (%) 
 
 
Glycyr- 
rhizin 
Liquiri-
tin 
Liquiritin 
apioside 
Iso- 
liquiritin 
Iso- 
liquiritin 
apioside 
Liquiri-
tigenin 
 
 
 
Glabri- 
gin 
Lico- 
chalcone  
A 
Glycy- 
coumarin 
Shosoin- 
licorice 
5.05 0.64 0.11 0.64 0.08 0.16 
 
n. d. n. d. n. d. 
G. glabra 
n = 17 
3.35 
± 1.62 
0.17 
± 0.15 
1.60 
± 0.69 
0.08 
± 0.05 
0.53 
± 0.24 
0.03 
± 0.02 
 
0.16 
± 0.10 
n. d. n. d. 
G. inflate 
n = 8 
3.27 
± 1.64 
0.27 
± 0.13 
1.47 
± 0.70 
0.04 
± 0.02 
0.51 
± 0.27 
0.04 
± 0.03 
 
n. d. 
0.85 
± 0.48 
n. d. 
G. uralensis 
n = 87 
3.43 
± 1.59 
1.74 
± 1.06 
1.30 
± 0.73 
0.33 
± 0.23 
0.41 
± 0.27 
0.11 
± 0.12 
 
n. d. n. d. 
0.09 
± 0.05 
 
Values indicated mean ± S. D. and n. d. meant no detected. 
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Figure 5.1.  Shosoin-licorice (Shosoin Medicament ML-44, N-99) 
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Figure 5.2.  DNA fragments (379 bp) of partial ITS region amplified by PCR. M: 100 bp DNA ladder 
marker, 1: G. uralensis (THS41990), 2: Shosoin-licorice. THS meant Tsumura 
herbarium specimen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
52 
 
 
     1    ITS1                                                  60 
G. glabra TCGATGCCTTGCAAGCAGTCCAACCTGTGAATCAGTTTGACTACATCGGGTTGGATTGGG 
G.inflata ............................................................ 
G. urelensis ............................................................ 
Shosoin L.  
 
             61                                        Forward primer    120 
G. glabra GTGTGCAACACCTCAACCTCCCTTGGGTTAGGAGGGGGCCACGCACTGTGTTCTCTCCTC 
G.inflata ............................................................ 
G. urelensis ............................................................ 
Shosoin L. . 
 
          121                                                         180 
G. glabra TTAGCCAAAACACAAACCCCGGCGCTGAATGCGCCAAGGAACTAAAATTCGTTCAGTGCG 
G.inflata ............................................................ 
G. urelensis ............................................................ 
Shosoin L. ............................................................ 
 
          181   site 1                                         5.8S     240 
G. glabra CCCCCGTCGGCCCGGAGACGGTGCTCGTGCGGGTGGCGTTTTGACACGTGATGCAGAATG 
G.inflata ............................................................ 
G. urelensis ......C..................................................... 
Shosoin L. ......C..................................................... 
 
          241                                                         300 
G. glabra ACTCTCGGCAACGGATATCTAGGCTCTTGCATCGATGAAGAACGTAGCGAAATGCGATAC 
G.inflata ............................................................ 
G. urelensis ............................................................ 
Shosoin L. ............................................................ 
 
          301                                                         360 
G. glabra TTGGTGTGAATTGCAGAATCCCGTGAACCATCGAGTCTTTGAACGCAAGTTGCGCCCGAA 
G.inflata ............................................................ 
G. urelensis ............................................................ 
Shosoin L. ............................................................ 
 
          361                                ITS2            site 2     420 
G. glabra GCCATTAGGCCAAGGGCACGTCTGCCTGGGTGTCACAGACCGTTGCCCGACAACAATTGC 
G.inflata ............................................................ 
G. urelensis ..................................................TGC....... 
Shosoin L. ..................................................TGC....... 
 
          421                                     Reverse primer        480 
G. glabra CTCGCGATAGGTACTTTGGTTGTGCAGGGTGAATGTTGGCTTCCCGTGAGCATTGCGGCC 
G.inflata ............................................................ 
G. urelensis ............................................................ 
Shosoin L. ................................. 
 
          481                                                         540 
G. glabra TCACGGTTGGCTCAAAACTGAGTCCATGGTAGGGTTTGGCATGATCGATGGTGGTTGAGT 
G.inflata ............................................................ 
G. urelensis ............................................................ 
Shosoin L.  
 
          541                                                         600 
G. glabra GACGCTCGAGACCAATCATGTGTGACTCCACTGAGTTTGGGCTCTGTAACCAATAGGCGT 
G.inflata ............................................................ 
G. urelensis ............................................................ 
Shosoin L.  
 
          541              616 
G. glabra CTTTGAACGCTCGTGA 
G.inflata ................ 
G. urelensis ................ 
Shosoin L.  
 
Figure 5.3.  ITS sequences of G. glabra, G. inflata, G. uralensis and the Shosoin-Licorice. 
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Figure 5.4.  Scatter diagram of the principal component analysis for the six main constituent contents 
of licorices identified from the total genotype (the chapter 4 in this thesis or Kondo et 
al., 2007a; n = 117) and the Shosoin-licorice. 
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Chapter 6 
 
Development of an easier discriminating method of botanical raw materials  
without DNA sequencing on the Japanese pharmacopoeia 
 
Discrimination between Atractylodes rhizome and Atractylodes lancea rhizome  
by the PCR-RFLP analysis of ITS region on nrDNA 
 
6.1  Introduction 
Dried rhizomes of Atractylodes macrocephala Koidz. (= A. ovata DC. in Asteraceae) and A. 
japonica Koidz. are used as the crude drug called Atractylodes rhizome (白朮, written in Chinese 
character), and A. lancea DC. and A. chinensis Koidz. called Atractylodes lancea rhizome (蒼朮, 
written in Chinese character) in the Japanese Pharmacopoeia (MHLW, 2016b). Discrimination 
between Atractylodes rhizome and Atractylodes lancea rhizome using molecular markers have been 
reported (Cheng et al., 1997; Mizukami et al., 2000). 
In the general information on the Japanese Pharmacopoeia (MHLW, 2016f), the purity test for 
Atractylodes rhizome by molecular biological method was established to stop commingling of 
Atractylodes lancea rhizome with Atractylodes rhizome. This purity test based on the amplification 
refractory mutation system (ARMS) detected the differences of nucleotide sequences on ITS among 
the medicinal Atractylodes species (Guo et al., 2006). The ARMS required rigorous experimental 
condition comparatively because the ARMS detected the nucleotide substitution by existence or 
nonexistence of PCR products using the specific mismatch primer. Therefore, to discriminate between 
Atractylodes rhizome and Atractylodes lancea rhizome, PCR restriction fragment length 
polymorphism (PCR-RFLP) as a simple, quick, and stable method was attempted. 
 
6.2  Materials and methods 
Materials 
Dried rhizomes of Atractylodes macrocephala (THS 83160-1), A. japonica (THS 83160-22), 
A. lancea (THS 83160-18) and A. chinensis (THS 82810-1) identified by their ITS sequences were 
prepared. Additionally, the hybrid between A. lancea and A. chinensis (THS 82811-2) was added as 
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a material because many natural hybrids are distributed in China (Shiba et al., 2006). THS meant 
Tsumura Herbarium specimen. The species identification by the ITS sequence followed in Shiba et 
al. (2006). 
Target site for PCR-RFLP analysis 
Based on the ITS sequences among the medicinal Atractylodes species (Shiba et al., 2006), two 
nucleotide sites were selected as species specific nucleotide substitutions that were digestible by 
restriction enzymes. Atractylodes lancea only has nucleotide ‘G’ at the 75th site which can be cut by 
the restriction enzyme FauI (recognition site: GCGGG, cut site: between the 64th and 65th), and 
Atractylodes chinensis only has nucleotide ‘C’ at the 94th site which can be cut by MspI (recognition 
site: CCGG, cut site: between the 93rd and 94th; Fig. 6.1). Primers were designed to amplify the 137 
bases of DNA fragment containing the two nucleotide sites. 5 ́-primer: 5 ́-GGC ACA ACA CGT GCC 
AAG GAA AA-3 ́, 3 ́-primer: 5 ́-CGA TGC GTG AGC CGA GAT ATC C-3 ́. 
DNA extraction and amplification 
For DNA extraction and amplification, Ampdirect® Plus enzyme kit (Shimadzu Biotech, 241-
08890-92) were applied. Ampdirect® Plus enzyme kit with Ampdirect® Plus and Nova TaqTM Hot 
Start DNA Polymerase allow simple and quick DNA extraction, and stable DNA amplification from 
crude drugs. Shredded crude drug material (20 mg) within SNET buffer (400 μL) incubated at 55 C̊ 
for overnight (about 16– 18 hr). The SNET buffer contains Tris-HCl pH 8.0 (20 mM), EDTA (5 mM), 
NaCl (400 mM), SDS (0.3 %) and Protainase K (200 μg/mL). Following the incubation, DNA 
polymerase was inactivated at 95 ̊C for 5 min. After precipitating solids by centrifuge, the supernatant 
was used as template DNA solution. Amount of DNA within the template DNA solution is difficult 
to estimate accurately by OD260 nm observation because the solution contains many foreign substances. 
The PCR mixture contained 2× Ampdirect® Plus described with MgCl2 and dNTP (10 μL), the 
avobe-descrived 5 ́- and 3 ́-primers (0.5 μM), Nova TaqTM Hot Start DNA Polymerase (0.5 units), 
the template DNA solution (0.5 μL), and added D. W. to 20 μL of total mixture volume. The PCR 
mixture was prepared under cool conditions. 
DNA amplification by PCR was carried out under the following conditions: pre-cycling 
denaturation at 95 ̊C for 10 min, 40 cycles of denaturation at 95 C̊ for 30 seconds, annealing at 65 C̊ 
for 15 seconds, and elongation at 72 C̊ for 7 min; and stored at 4 ̊C. 
Digestion with the restriction enzyme 
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For the digestion of the PCR products by FauI (New England BioLabs Inc.), a 15 μL reaction 
containing 3 μL template DNA, one unit of enzyme and 1× SEBuffer B was incubated at 55 C̊ for 2 
hr. For MspI (New England BioLabs Inc.), a 15 μL reaction containing 3 μL template DNA, 20 units 
of enzyme and 1× NEBuffer B was incubated at 37 C̊ for 2 hr. After the incubation, the enzymes were 
inactivated at 72 ̊C for 10 min. The digested DNA fragments were detected by electrophoresis using 
E-gel® 4% agarose (Invitrogen). 
 
6.3  Results 
The PCR products of the medicinal Atractylodes species digested by the restriction enzyme 
FauI and MspI were indicated on an electrophoretic profile (Fig. 6.2). All of the PCR products of 
Atractylodes rhizome derived from A. macrocephala and A. japonica were not digested by FauI or 
MspI, and were observed as one band (137 bp) on the electrophoretic profile. In Atractylodes lancea 
rhizome, the PCR products of A. lancea were digested by FauI only and were observed as the three 
bands (137, 77, and 62 bp) on the electrophoretic profile. The PCR products of A. chinensis were 
digested by MspI only and were observed as the three bands (137, 91, and 48 bp) on the 
electrophoretic profile. The PCR products of the hybrid between A. lancea and A. chinensis were 
digested by FauI and MspI, and were observed as three bands. 
 
6.4  Discussion 
Digestion of PCR products of A. lancea and A. chinensis by FauI or MspI expected that two bands 
would be observed on the electrophoretic profile. However, in this study, the PCR products of A. 
lancea and A. chinensis produced digestion of the three bands on the electrophoretic profile (Fig. 6.2). 
According to the expected length of digested band, the shorter two bands were derived from the 
digestion by FauI or MspI. The longest bands (137 bp) would be derived from the undigested PCR 
products. These undigested PCR products were not digested under different experimental conditions 
that the enzyme reaction times were set longer or amount of the enzymes were increased. It has been 
suggested that the ITS sequences in A. macrocephala and A. japonica is ancestral phylogenetically 
from A. lancea or A. chinensis (Shiba et al., 2006). Atractylodes lancea and A. chinensis would retain 
the ancestral minor ITS copy which is indigestible by FauI or MspI. 
Though remaining the undigested PCR products, the three bands derived from the digestion of 
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the PCR products by FauI or MspI were recognized as A. lancea, A. chinensis and their hybrid. Thus, 
the discrimination between Atractylodes rhizome derived from A. macrocephala and A. japonica, and 
Atractylodes lancea rhizome derived from A. lancea and A. chinensis was possible by the PCR-RFLP 
analysis using FauI and MspI. On the electrophoretic profile after the enzyme reaction by FauI and 
MspI for the PCR products, one band only was recognized with Atractylodes rhizome, 2 or 3 bands 
were recognized on the reaction of FauI or MspI with Atractylodes lancea rhizome. 
Additionally, in this PCR-RFLP method, the hybrids between Atractylodes rhizome derived from 
A. macrocephala or A. japonica and Atractylodes lancea rhizome derived from A. lancea or A. 
chinensis would be difficult to identify because the electrophoretic profile of the hybrids would show 
the same three bands observed in A. lancea or A. chinensis mentioned above. 
Consequently, this PCR-RFP method was described as a purity test on crude drugs using genetic 
information in the general information of Japanese pharmacopoeia (MHLW, 2016f). 
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  1         primer site                                        70 
A. lancea CCCCGGCACAACACGTGCCAAGGAAAACAAAACTTAAGAAAGGCGCTTCTCGTGTCGCCCCGTTCGCGGT 
A. chinensis .....................................C................................ 
A. macrocephala ........................................G............................. 
A. japonica ...................................................................... 
Hybrid .....................................M................................ 
 
         71                                               primer site    145 
A. lancea GCGGGCATGGGTCGTGGCCTCTCTGGAAACACAAACGACTCTCGGCAACGGATATCTCGGCTCACGCATCGATGA 
A. chinensis ...C...................C................................................... 
A. macrocephala ...C....................................................................... 
A. japonica ...C....................................................................... 
Hybrid ...S...................Y................................................... 
FauI              MspI 
 
Figure 6.1.  Amplified DNA region and recognition sites by FauI and MspI on the ITS sequences in 
the Atractylodes species. The triangle means cut sites by FauI and MspI. Hybrid was a 
derivative between A. lancea and A. chinensis. 
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Figure 6.2.  Electrophoretic pattern in the Atractylodes species. 1, 12: DNA ladder (20 bp). 2, 3: 
A. macrocephala (FauI, MspI). 4, 5: A. japonica (FauI, MspI). 6, 7: A. lancea (FauI, 
MspI). 8, 9: A. chinensis (FauI, MspI). 10, 11: Hybrids between A. lancea and A. 
chinensis (FauI, MspI). 
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Chapter 7    
 
Exclusion of fake raw materials 
 
Discrimination between Banxia and Tiannanxing based on rbcL sequences 
 
7.1  Introduction 
Crude drugs of Banxia（半夏, written in Chinese character）, Zhangyebanxia (掌葉半夏, written in 
Chinese character), Shuibanxia (水半夏, written in Chinese character), and Tiannanxing (天南星, 
written in Chinese character) are derived from the tubers of Araceae species. In the Japanese 
Pharmacopoeia, Pinellia ternata was prescribed as the original plant of Banxia (MHLW, 2016e; 
Chinese pharmacopeia commission, 2015d). Shuibanxia, Zhangyebanxia, and Tiannanxing have been 
regarded as tubers of Typhonium sp., Pinellia pedatisecta, and Arisaema sp., respectively (Jiangsu 
new medical college, 1977; Institute of materia medica, 1982; Chinese pharmacopeia commission, 
2015b). Tiannanxing resembles Banxia very closely and sometimes distributes as Banxia or is mixed 
within Banxia on the markets. Therefore, in this study, discrimination between Banxia and 
Tiannanxing by a molecular marker was attempted. A part of rbcL sequence was applied as the 
molecular marker. The original plants of Banxia and Tiannanxing belong different genera and the rbcL 
is known as a useful gene for identification of the higher taxa than species (Soltis et al., 1990). 
 
7.2  Materials and methods 
Materials 
The rbcL sequences of 27 plants and 30 crude drug samples relating to Banxia were assayed. The 
plants were identified from their morphological characters including the original plants of Banxia or 
Tiannanxing (Table 7.1). The crude drugs examined were Banxia, Zhangyebanxia, Shuibanxia, and 
Tiannanxing commercially obtained in the markets (Table 7.2). Those crude drugs were grouped into 
four types according to their appearance (Types A, B, C, and D; Fig. 7.1). Type A tubers were white 
spheroidal tubers of diameters less than 2 cm. Type B tubers were yellowish brown spheroidal tubers 
of diameters above 2 cm. Type B tubers usually had some small spheroidal tubers beside the main 
tubers. Type C tubers were light brown ellipsoidal tubers of diameters less than 2 cm. Type D tubers 
were light brown or white spheroidal tubers of diameters above 2 cm. 
DNA extraction 
DNA was extracted from fresh leaves or herbal specimens of about 4cm2 and the crude drugs of 
about 1 g by grinding with 1 ml of CTAB buffer (2x). These mixtures were centrifuged at 15,000 rpm 
for 5 minutes and 500 µl of the supernatants were transferred to fresh tubes. These supernatants were 
mixed with 500 µl of isopropanol. After centrifugation at 15,000 rpm for 5 minutes, the pellets were 
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vacuum dried and the residue was dissolved in 20 µl TE buffer (Watanabe et al., 1989). 
DNA amplification and sequencing 
The 154 base pairs of the rbcL gene between 709 and 836 from the start codon of Nicotiana 
tabacum (Shinozaki et al., 1986) were amplified by PCR. The amplified fragments were including 
inter-genus substitutions between Pinellia and Arisaema. PCR primers for the amplifying DNA were 
5’-GGG CAT TAC TTG AAT GCT ACT G-3’ and 5’-CCA TTG TCT CGG CAA TAA TGA GC-3’. 
The PCR was performed under the following condition: 94°C for 2 minutes, and 60°C for 3 minutes, 
for 35 cycles. The amplified DNA fragments were purified by MERmaid Spin Kit (BIO101) and 
sequenced by using the Taq DyeDeoxy Terminator Cycle Sequencing Kit and 373A DNA sequencer 
(Applied Biosystems Division, PERKIN ELMER). 
 
7.3  Results 
Sequence types of rbcL recognized in plant and crude drug materials 
Seven types of the rbcL sequences (Type 1–7; Fig. 7.2) were observe from the 57 samples 
examined. 
In the plant materials (Table 7.1), sixteen plants of Pinellia ternate had the sequence type 1 and 
2 of rbcL that would be intraspecific variations. Pinellia cordata, P. pedatisecta, and P. tripartita had 
the sequence type 3. Typhonium divaricataum had the sequence type 5. Arisaema serratum had the 
sequence type 6. Arisaema amurense, A. erubescens, A. negishii, and A. thunbergii var. urashima had 
the sequence type 7. 
Meanwhile, in the crude drug materials (Table 7.2), eleven of Banxia with the appearance type A 
had the sequence type 1 and 2 of rbcL. Seven of Tiannanxing and a Zhangyebanxia with the 
appearance type B had the sequence type 3. A Shuibanxia with the appearance type C had the sequence 
type 4. Three of Banxia with the appearance type A and seven of Tiannanxing with the appearance 
type D had the sequence type 7.  
Additionally, about the crude drugs except Banxia or Tiannanxing, a Shuibanxia with the 
appearance type C and sequence type 4 would be derived from Typhonium species. Seven of 
Tiannanxing and a Zhangyebanxia with the appearance type B and the sequence type 3 would be 
Zhangyebanxia derived from Pinellia pedatisecta. 
Fake raw materials mixed within Banxia 
From the results of the plant materials (Table 7.1), Pinellia ternata which is original plant of 
Banxia had the sequence type 1 or 2 of rbcL and Arisaema amurense, A. erubescens, and A. 
heterophyllum those are original plants of Tiannanxing had the sequence type 7. Therefore, in the 
crude drug materials (Table 7.2), the three crude drugs named Banxia with the appearance type A and 
the sequence type 7 were presumed that they were not Banxia derived from Pinellia ternata but 
Tiannanxing derived from Arisaema species. 
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In this research, it was recognized that the small sized tubers derived from Arisaema species 
closely resembled to Banxia and were distributed as Banxia (Fig. 7.3). They were produced in Anhui 
and Guizhou provinces in China. Guizhou province is known as a main producing district of Banxia 
and Tiannanxing (China Natural Corporation of Traditional Medicament, 1996).  
Morphological differences between Small size Tiannanxing and Banxia 
The appearances of the small sized Banxia derived from Arisaema species identified by their 
rbcL sequences were observed anew in detail. They had a big stem scar and one-lined big root scars 
(Fig. 7.3). While, Banxia derived from Pinellia ternata had comparatively a small stem scar and 
scatted small root scars.  
 
7.4  Discussion 
The discrimination between Banxia and Tiannanxing was possible by comparing their rbcL 
sequences. Consequently, it was revealed that small sized Tiannanxing were distributed as Banxia or 
mixed within Banxia because the appearance of small sized Tiannanxing resembled to Banxia. In the 
regions producing both of Banxia and Tiannanxing, careful attention is required to contaminations of 
Banxia and Tiannanxing each other. 
Meanwhile, research of the rbcL sequence for all individuals in a crude drug lot is impossible 
because those are too many. In this case, at first, Banxia and small sized Tiannanxing were 
discriminated morphologically by reviewing the appearance of the crude drug distinguished by the 
genetic information. The new morphological characteristics for the discrimination between the both 
crude drugs were given to the sorting site of the crude drug producing company. Finally, the exclusion 
of the fake raw materials those were small sized Tiannanxing from Banxia became possible. 
Exclusion of fake raw material required not only discrimination of the crude drugs by the genetic 
information but also translation from the discrimination information to a realistic exclude application 
on GACP or GMP. 
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Table 7.1.  Sequence types of the rbcL gene of plants identified by their morphological features. 
 
Sequences Species Locarity Voucher* 
Type 1 Pinellia ternata (Thunb.) Breit. Japan 40251, F 
 Pinellia ternata (Thunb.) Breit. Japan 40252, F 
 Pinellia ternata (Thunb.) Breit. Japan 40253, F 
 Pinellia ternata (Thunb.) Breit. Japan, Ibaraki 39273, F 
 Pinellia ternata (Thunb.) Breit. Japan, Ibaraki 29281, F 
 Pinellia ternata (Thunb.) Breit. Japan, Ibaraki 40255, F 
 Pinellia ternata (Thunb.) Breit. Japan, Shizuoka 40254, F 
 Pinellia ternata (Thunb.) Breit. China, anhui 40257, F 
 Pinellia ternata (Thunb.) Breit. China, Fujian 39276, F 
 Pinellia ternata (Thunb.) Breit. China, Guizhou 40259, F 
 Pinellia ternata (Thunb.) Breit. China, Hubei 40260, F 
 Pinellia ternata (Thunb.) Breit. China, Sichuan 38727, H 
 Pinellia ternata (Thunb.) Breit. China, Sichuan 40258, F 
Type 2 Pinellia ternata (Thunb.) Breit. China, Henan 25270, H 
 Pinellia ternata (Thunb.) Breit. China, Yunnan 39274, F 
 Pinellia ternata (Thunb.) Breit. China, Yunnan 40256, F 
Type 3 Pinellia cordata E. Br. cultivated** 39280, F 
 Pinellia pedatisecta Schott China, Yunnan 40250, F 
 Pinellia tripartita (Blume) Schott cultivated** 40248, F 
Type 5 Typhonium divaricatum (L.) Decne cultivated** 40261, F 
Type 6 Arisaema serratum (Thunb.) Schott Japan, Fukushima 39269, F 
 Arisaema serratum (Thunb.) Schott Japan, Fukushima 40294, F 
Type 7 Arisaema amurense Maxim. subsp. sobustum (Engler) Ohashi et J. Murata 
  Japan, Niigata 39278, F 
 Arisaema erubescens (Wall.) Schott China, Sichuan 25208, H 
 Arisaema heterophyllum Blume China, Jangxi 25207, H 
 Arisaema negishii Makino cultivated** 39270, F 
 Arisaema thunbergii Blume subsp. urashima (Hara) Ohashi et J. Murata 
  Japan, Kanagawa 39279, F 
 
*  Referance number of herbarium specimen of Tsumura & Co. (THS). “F” and “H” represented  
the DNA extracted from fresh leaves or herbarium specimens, respectively. 
** Culutivated in Tsumura herb garden. 
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Table 7.2.  Sequnce and appearance types of crude drug examined. 
 
Sequence Trade name Market Voucher* Appearance 
Type 1 Banxia Japna, Iwate 13938 A 
 Banxia China, Gansu 15506 A 
 Banxia China, Hubei 15490 A 
 Banxia China, Shanghai 13536 A 
 Banxia China, Shanghai 15508 A 
 Banxia China, Yunnan 15139 A 
Type 2 Banxia China, Guizhou 15494 A 
 Banxia China, Shanghai 15503 A 
 Banxia China, Yunnan 15498 A 
 Banxia China, Yunnan 13849 A 
 Banxia China, Zhejiang 14542 A 
Type 3 Tiannanxing China, Hebei 13129 B 
 Tiannanxing China, Henan 8218 B 
 Tiannanxing China, Henan 14656 B 
 Tiannanxing China, Henan 15554 B 
 Tiannanxing China, Henan 6855 B 
 Tiannanxing China, Hongkong 14660 B 
 Tiannanxing China, Hongkong 15614 B 
 Zhangyebanxia China, Bejing 6890 B 
Type 4 Shuibanxia China, Guangxi 15252 C 
Type 7 Banxia China, Anhui 15550 A 
 Banxia China, Guizhou 8956 A 
 Banxia China, Guizhou 15553 A 
 Tiannanxing China, Guizhou 10367 D 
 Tiannanxing China, Guizhou 10368 D 
 Tiannanxing China, Guizhou 14657 D 
 Tiannanxing China, Guizhou 15557 D 
 Tiannanxing China, Hongkong 14661 D 
 Tiannanxing China, Sichuan 9707 D 
 Tiannanxing China, Yunnan 7740 D 
 
* Reference number of Herbariu specimen of Tsumura & Co. (THS). 
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Type A                Type B 
   
Type C                            Type D 
 
Figure 7.1.  Appearace types of the crude drugs derive from Araceae speceis. Bars meant 1 cm. 
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1    primer site                                                      80 
Type 1 GGGCATTACTTGAATGCTACTGCAGGTACGTGTGAAGAAATGATGAAAAGAGCTGTGTTTGCCAGAGAATTGGGAACCCC 
Type 2 ............................................C................................... 
Type 3 ............................................C..............................G.... 
Type 4 ............................................C.....G............................. 
Type 5 ............................................C.....G........................G.... 
Type 6 ..................................................G........................GT... 
Type 7 ............................................C.....G........................GT... 
 
      81                                                primer site   154 
Type 1 TATCGTAATGCATGACTATTTAACAGGGGGATTCACTGCAAATACTAGTTTAGTCATTATTGCCGAGACAATGG 
Type 2 .......................................................................... 
Type 3 ..........................................................................  
Type 4 .......................................................................... 
Type 5 ..................C.................C..................................... 
Type 6 ..................C....................................................... 
Type 7 ..................C....................................................... 
 
 
Figure 7.2.  Types of the rbcL sequences obtained from the 57 sample examied. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
 
 
Tiannanxing              Banxia 
 
   Figure 7.3.  Appearaces of small sized Tiannanxing and Banxia. Bar meant 1 cm. 
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Chapter 8     
 
Operation procedure of species identification on GACP or GMP 
 
Operation procedure of species identification on a suitable GACP  
for herbal medicinal product manufacturing 
 
8.1  Introduction 
In herbal medicinal product manufacturing, a quality control of a botanical raw material (BRM), 
including medicinal plants and herbal substances, is essential to ensure consistent quality of herbal 
medicinal products. In particular, agricultural BRM production processes strongly affect the quality of 
BRM and can influence the consistency of herbal medicinal products. Hence, implementation of good 
agricultural and collection practices (GACP) to BRM production is recommended as quality assurance 
systems (PIC/S, 2017a). GACP guidelines are available from the European medicines agency (EMA, 
2006) and the World health organization (WHO, 2003), and from various other agencies. 
BRM that are starting materials for herbal medicinal products should comply with good 
manufacturing practices (GMP). Thus, to confirm that the required controls are present in GACP for 
herbal medicinal products, I reviewed requirements for GACP in the GMP guidelines provided by the 
Pharmaceutical inspection convention/Pharmaceutical inspection co-operation scheme (PIC/S), the 
international council for harmonization of technical requirements for pharmaceuticals for human use 
(ICH), and the development guidance for herbal medicinal products from the U. S. Food and drug 
administration (FDA).  
In this study, at first, international guides concerning GACP for herbal medicinal product 
manufacturing were reviewed and quality controls of the GMP guidance with those of the EMA and 
WHO GACP guidelines were compered. Consequently, a suitable GACP for herbal medicinal products 
was proposed. Additionally, in the suitable GACP, operation procedure of the species identification 
for botanical raw material was proposed. 
 
8.2  Reviews of international guides concerning GACP 
Requirements for GACP according to GMP guidelines for herbal medicinal products GMP from 
the PIC/S 
Japan became the 45th PIC/S participating authority in July 2014 following special consideration 
of the globalization of pharmaceutical manufacturing. However, to apply for membership, Japan’s 
GMP inspectorate needs to fulfill PIC/S GMP requirements (Katori, 2014). Moreover, the Japanese 
ministry of health, labor and welfare (MHLW) announced requirements for application of and 
compliance with the PIC/S GMP guidance as GMP ministerial ordinances (MHLW, 2012 and 2013). 
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In Annex 7 of the PIC/S GMP guidance for herbal medicinal products (PIC/S, 2017a), starting 
materials are defined as medicinal plants, herbal substances, or herbal preparations, and the 
requirements for GACP are described as follows: Application of GACP from EMA, WHO, or 
equivalent authorities is recommended, and GACP apply to cultivation, collection, harvesting, cutting, 
and drying of plants, algae, fungi, lichens, and exudates. In contrast, GMP apply to expression, 
extraction, purification, concentration, or fermentation of starting materials, and documentation of 
starting material specifications and processing instructions are required for processes, such as cleaning, 
drying, crushing, and sifting. Additionally, the manufacturing processes should verify, where 
appropriate, whether suppliers of starting materials are compliant with GACP. 
Pharmaceutical quality systems of ICH and FDA 
Pharmaceutical quality system (PQS) is provided by the ICH as quality guideline ICH-Q10 (ICH, 
2008) and by the FDA as the guidance for industry (FDA, 2009). The ICH-Q10 section describes a 
comprehensive model for an effective PQS that is based on quality concepts of the International 
standards organization (ISO) and includes applicable GMP regulations. Implementation of PQS 
throughout medicinal product lifecycles should facilitate innovation and continual improvement, and 
may strengthen links between pharmaceutical development and manufacturing activities. In 2010, the 
Japanese MHLW announced that ICH-Q10 includes applicable GMP regulations and complements the 
pharmaceutical developments in ICH-Q8 and the quality risk management strategies in ICH-Q9 
(MHLW, 2010; ICH, 2009; ICH, 2005b). 
ICH-Q10 provides guidelines for implementation of PQS in frameworks for the following 
outcomes: (1) pharmaceutical quality system; (2) management responsibility; (3) continual 
improvement of process performance and product quality; and (4) continual improvement of PQS. 
Although ICH-Q10 does not specify GACP, the frameworks of PQS should be applicable to GACP 
for herbal medicinal products. 
The botanical drug development guidance from the FDA 
The FDA provides a botanical drug development guidance for industry (FDA, 2016) and 
describes current considerations of the center for drug evaluation and research regarding appropriate 
development plans for a botanical drugs with potential as new drug application (NDA). The guideline 
also provides specific recommendations for submission of investigational new drug in support of 
future NDA submissions for botanical drugs. 
This FDA guidance states the requirements for BRMs in each phase of botanical drug 
development. In particular, quality control of botanical drug products starts with the raw materials and 
should be described in the NDA. Specific information for medicinal plants should be identified, such 
as that required for verification of authentic morphology, macroscopic, microscopic, and chemical 
analyses, and agricultural practices such as cultivation, harvesting, and storage conditions, geographic 
locations, and collection and processing methods. Accordingly, applicants are required to establish 
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GACP and summarize related procedures for each of the BRMs during submission of an NDA. 
Moreover, general GACP principles from the WHO (2003), EMA (2006), and the local regulatory 
body should be referenced. 
Reviews of botanical drugs from the FDA 
The FDA approved the botanical drugs Veregen and Fulyzaq in 2006 and 2012, respectively. 
Veregen is a proprietary extract of Camellia sinensis Kuntze and is use as a treatment for genital and 
perianal warts (Austin, 2006). Fulyzaq is a proprietary extract of the blood-red latex of Croton lechlerii 
Müll, and is a novel indication for HIV-associated diarrhea (Austin, 2013). 
Prior to approval of Veregen, the FDA required that all cultivars of BRMs that were used in 
clinical studies should be identified, and BRMs for future batches should be limited to these cultivars 
and to the farms that provided the clinical trial material. Moreover, any changes in cultivars or farms 
of BRMs should be approved by the FDA first. These control measures are designed to reduce 
variability at the BRM level (Dou, 2006). Because plant growth and composition can be affected by 
soil, weather, seasonal variations, geographic location, and other agricultural practices, batch-to-batch 
inconsistency is a common problem. Hence, manufacturers could achieve adequate quality control of 
botanical starting materials by applying the principals outlined in the FDA botanical guidance and by 
applying GACP for starting materials of botanical origin (Chen et al. 2008). 
Prior to approval of Fulyzaq, the botanical review of FDA required sufficient details (Dou, 2012) 
from the WHO GACP guidelines, field manuals on how to identify BRMs, collection procedures, 
pesticides/defoliant questionnaires, and details for training of field collectors and for storage and 
transportation of BRMs. In addition, the harvesting area of the BRM was restricted to specific eco-
geographic regions (EGRs) to reduce variability at the BRM level. However, because BRMs of 
Fulyzaq were collected in the wild, more detailed information is required to better define the EGRs, 
and it was requested that these details include the global positioning system (GPS) coordinates and 
borders of collection sites (Lee, 2015). 
 
8.3  Control comparison between PIC/S GMP and GACP guidelines 
Representative GACP guidelines were provided from the EMA and the WHO in 2006 and 2003, 
respectively. However, the GMP guidance for medicinal products is updated annually in keeping with 
newer quality control approaches from the PIC/S and the ICH. Thus, the EMA and WHO GACP 
guidelines should be revised to ensure compliance with newer quality control approaches. The EMA 
GACP guideline states that to ensure appropriate and consistent quality of the BRM, GMP for active 
pharmaceutical ingredients (APIs) are also applicable. Accordingly, the manufacturing guidance for 
APIs is provided as Part II of the PIC/S GMP guidance (PIC/S, 2017b). Therefore, I compared controls 
in Part II of the PIC/S GMP guidance with those from EMA and WHO GACP guidelines (Table 8.1). 
These comparisons revealed that the GACP guidelines lack eight controls from Part II of the 
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PIC/S GMP guidance (Table 8.1), including (1) laboratory controls, (2) validation, (3) change control, 
(4) rejection and re-use of materials, (5) complaints and recalls, (6) specific guidance for APIs 
manufactured by cell culture/fermentation, (7) agents, brokers, traders, distributors, repackers, and 
relabellers, and (8) APIs for use in clinical trials. In particular, GACP guidelines stipulate only 
production processes with minimal quality controls, and lack GMP level approaches to production 
process and quality controls. These risk management systems and PQS are required for APIs of herbal 
medicinal products, and relevant controls are detailed in ICH-Q7, Q9, and Q10 (ICH, 2005a, 2005b, 
and 2008) and should be introduced to GACP for herbal medicinal products. 
In the absence of these eight controls, all but the specific guidance for APIs manufactured by cell 
culture/fermentation should be complementary to GACP controls. Cell culture/fermentation 
requirements are listed in the “manufacture of biological medicinal substances and products for human 
use” section of Annex 2 of the PIC/S GMP guidance, but are not listed for herbal medicinal products. 
Controls that are recommended for GACP in herbal medicine production are presented in Table 8.1. 
In the introduction of Annex 7 from the PIC/S GMP guidance, the scope indicates that GACP is 
to be applied to cultivation, collection and harvesting, cutting, and drying, whereas GMP for APIs are 
applied to expression, distillation, fractionation, purification, concentration, and fermentation. GMP 
is applicable to further cutting and drying steps and manufacturers should ensure that these steps are 
performed in accordance with the marketing authorization and registration. Moreover, it is the 
responsibility of the manufacturer of the medicinal product to ensure that the appropriate GMP 
classification is applied. 
Part II of the PIC/S GMP guidance includes sections regarding quality risk management, the 
responsibilities of quality units and production activities, and those of internal audits and product 
quality reviews. This quality management guideline also includes risk management (ICH-Q9) and 
PQS (ICH-Q10). In contrast, in the EMA and WHO GACP guidelines, quality agreements between 
producers and buyers of medicinal plants/herbal substances are the only quality assurances. Hence, 
risk management and PQS should be included in quality management procedures of GACP. 
The EMA and WHO GACP guidelines require control of facilities and equipment for processing 
after harvesting of BRM to prevent contamination, quality deterioration, and pest damage, but do not 
provide guidance on computerized systems. Hence, GACP related computerized systems for 
traceability and other records should be validated as appropriate. In addition, EMA and WHO GACP 
guidelines require that collectors of wild species must be able to differentiate between collected species 
and botanically related and/or morphologically similar species to avoid risks to public health. 
In terms of documentation and records requirements, all agricultural and collection activities 
relating to GACP must be recorded, and traceability of starting materials, production, and in-process 
batches must be recorded completely. Finally, traceability guidelines generally refer to GS1 global 
traceability standards for healthcare (GS1, 2013). 
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In materials management sections, particular attention should be paid to the management of seeds 
and propagation of starting materials for BRM production. Moreover, compliance is required with 
conventions on international trade in endangered species of wild fauna and flora (CITES) and with the 
convention on biological diversity (CBD). Finally, endangered medicinal plant species must be 
sourced only in accordance with national and/or regional legislation (WHO, 2003) and traceability of 
seeds and cultivars must be managed with approval of their receipt and derivation. 
Production instructions should be prepared for production control, and these must include 
cultivation or collection areas and identify the cultivators and collectors. Accordingly, the FDA 
recommends using GPS information to identify cultivation or collection areas (Lee, 2015), and tight 
controls for pesticide use during cultivation are required to ensure the safety of BRM. Hence, the 
identified cultivators must correctly record pesticide uses. 
Neither EMA nor WHO GACP includes guidelines for laboratory controls, validation, change 
control, rejection and re-use of materials, or complaints and recalls. To comply with appropriate PIC/S 
GMP guidance, these controls must complement GACP for herbal medicinal products. Moreover, 
laboratory controls should be applicable to all specifications, sampling plans, and test procedures that 
are scientifically sound and appropriate for ensuring quality of BRM. Specifically, validation 
procedures should be applicable to those determined as critical to the quality and purity of the BRM, 
change control procedures must evaluate all changes that may affect production and control of the 
BRM, and all rejections and re-uses of starting materials or intermediates of BRMs should be 
identified and recorded. All quality related complaints, whether received orally or in writing, should 
be recorded and investigated according to a written procedure. Specifically, the recall procedure must 
designate personnel to evaluate the information, decide how to initiate recall, who should be informed 
about the recall, and how the recalled material should be treated. 
In terms of contract manufacturers, Annex 7 of the PIC/S GMP guidance stipulates that 
comprehensive audits of herbal starting material suppliers must be performed by or on behalf of the 
herbal medicinal product manufacturer, and that the resulting documentation should be made available. 
Audit trails for active substances are fundamental to the quality of starting materials. Moreover, good 
agricultural practice (GAP) include audits and certifications that are generally conducted by third 
parties. Hence, this third-party audit and certification system might be introduced into GACP. 
EMA or WHO GACP guidelines do not control agents, brokers, traders, distributors, repackers, 
or relabellers, and all parties who trade and/or take possession, repack, relabel, manipulate, distribute, 
or store BRMs other than the original manufacturer should maintain complete traceability of all BRMs 
and intermediates that they distribute. 
Part II of the PIC/S GMP guidance mentions that raw materials of APIs for use in clinical trials 
must be evaluated by testing, or must be received with a supplier’s analysis and subjected to identity 
testing. In some instances, the suitability of a raw material can be determined before use based on 
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acceptability in small-scale reactions. 
 
8.4  A suitable GACP 
Applicable GACP guidelines 
The EMA or the WHO provide representative GACP guidelines for medicinal plants and other 
GACP guidelines include those from the Chinese general committee of the state administration of 
pharmaceutical supervision (2002) and those from the Japan Kampo manufacturing association 
(JKMA, 2014). The most recent draft of the WHO guidelines on good herbal processing practices 
(GHPP) for herbal medicines was announced in March 2017 (WHO, 2017), and states that GHPP are 
integral to GACP for medicinal plants, and to GMP quality assurance and control of herbal medicines. 
Thus, sections of the WHO GHPP guideline regarding processing of herbs into herbal materials and 
parts of herbal materials into herbal preparations should be referenced as an available GACP guideline 
for herbal medicinal products. 
Concerning applications of GAP to vegetable and other agricultural products, the GLOBAL 
G.A.P. was approved by the Global food safety initiative (GFSI) and has become the de-facto standard. 
GLOBAL G.A.P. adopts an efficient risk management strategy based on the regulation of GFSI. 
Similarly, the Japanese good agricultural practice (JGAP) is a GAP certification that is specific for 
Japanese agriculture. However, none of these GAP documents have specific instructions for medicinal 
plants. 
In accordance with GACP guidelines for herbal medicinal products, PIC/S participating 
authorities and applicants of FDA NDAs are instructed to comply with EMA or WHO GACP 
guidelines. However, the present comparisons indicate that EMA and WHO GACP guidelines lack 
some of the controls that are required by the PIC/S GMP guidance for the manufacture of APIs. 
Additionally, the WHO GHPP guideline was introduced as a newer processing guidance for herbal 
medicinal products. Therefore, in addition to EMA or WHO GACP guidelines, applicable GACP 
guidelines for herbal medicinal products should comprise Part II and Annex 7 of the PIC/S GMP 
guidance and the WHO GHPP guideline. 
GACP compliance with PQS (ICH Q10) 
In comparisons with the PIC/S GMP guidance, EMA and WHO GACP guidelines lack concepts 
of PQS. However, PQS are the most important quality control approach for medicinal product 
manufacturing and should be applied to GACP for herbal medicinal products. 
PQS apply to the development and manufacture of APIs and herbal medicinal products 
throughout the product lifecycle, and ICH-Q10 provides a harmonized model for PQS (ICH, 2008). 
Hence, implementation of the ICH-Q10 model should result in product realization and establishment 
and maintenance of a state of control, and should facilitate continual improvement. Moreover, ICH-
Q10 augments GMPs or GACPs by describing specific PQS elements and management 
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responsibilities. Thus, knowledge and quality risk management will enable companies to implement 
the ICH-Q10 model effectively and successfully. Elements of PQS include (1) process performance 
and product quality monitoring systems, (2) corrective action and preventive action (CAPA) systems, 
(3) change management systems, and (4) management review of process performance and product 
quality. 
To assess process performance and product quality, a well-defined system should be applied to 
assure performance within a state of control, and to identify improvement areas. Accordingly, good 
process performance on GACP involves suitable conduct of all agricultural and collection activities 
based on production instructions. To ensure good process performance during production of BRM, the 
production records should be monitored at control points based on hazard analysis critical control 
point and quality checks of BRM specifications. Thus, BRM production companies should have 
systems for implementing CAPA following investigations of complaints, product rejections, non-
conformances, recalls, deviations, audits, regulatory inspections and findings, and trends from process 
performance and quality monitoring of BRMs. Accordingly, the FDA guideline includes an entry-level 
instruction about CAPA under the heading “Corrective and preventive action basics” in GLOBAL 
G.A.P. 
Change is driven by innovation, continual improvement, and the outputs of process performance, 
product quality monitoring, and CAPA. To evaluate, approve, and implement these changes properly, 
companies should have effective change management systems (ICH, 2008). In particular, when 
production methods and cultivation or collection areas are applied, quality risk management should 
be used to confirm that the changes do not influence BRM quality. Similarly, after implementation, 
changes should be assessed to confirm that the objectives were achieved and that BRM quality was 
maintained. Moreover, a management review should be provided to assure that process performance 
and product quality are managed throughout the lifecycle of the BRM. Accordingly, senior managers 
should establish management commitments, quality policies, and quality planning for GACP, and take 
responsibility for resource management. Finally, quality policies for GACP should be established with 
consideration of overall quality intentions and directions of the company. 
Knowledge management is a systematic approach to acquiring, analyzing, storing, and 
disseminating information related to BRMs, production processes, and production components. 
Quality risk management is a proactive approach to identifying, scientifically evaluating, and 
controlling potential risks to quality. However, risk management strategies are not present in the EMA 
or WHO GACP guidelines. Thus, the GFSI emphasizes risk management as part of GAP, and 
advocates proactive application of risk management to suitable GACP for herbal medicinal products. 
The EMA and the WHO provide representative guidelines for GACP. However, these GACP 
guidelines are limited to production processes with minimal quality control, and fail to subscribe GMP 
levels for production and quality control processes that contribute to risk management and PQS. 
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Therefore, to implement suitable GACP for herbal medicinal products, applicable GACP guidelines 
should comprise Part II and Annex 7 of the PIC/S GMP guidance, the EMA or WHO GACP guidelines, 
and the WHO GHPP guideline. Additionally, it is essential that PQS concepts are complementary to 
GACP, because they are the most important quality control approaches for medicinal product 
manufacturing. 
The basically management system for the suitable GACP was illustrated in Fig. 8.1. PIC/S GMP 
part II was applicable as the GACP management policy. Factory, production company of raw materials, 
and farmer would realize the GACP management policy by using the PQS elements. 
 
8.5  Operation procedure of the species identification in the suitable GACP or GMP 
In the suitable GACP, species identification of raw material of herbal medicinal product should 
be performed in accordance with PQS. The four phases of (1) Pharmaceutical development, (2) 
Technology transfer, (3) Commercial manufacturing, and (4) Product discontinuation were defined as 
life cycle of herbal medicinal product in PQS (Fig.8.2). In the phase of pharmaceutical development, 
scientific name, chemical property, and methods of species identification and purity test for a raw 
material should be confirmed or configured. In the phase of commercial manufacturing, the species 
identification or purity test should be examined for raw materials of herbal medicinal products. 
Especially, in the phase of commercial manufacturing, the herbal medical product manufacturing 
would be managed by GACP in famer and production company producing raw materials of herbal 
products to factory, by GMP in factory manufacturing herbal products, by good distribution practice 
(GDP), good vigilance practice (GVP), good post-marketing study practice (GPSP) after the herbal 
product delivery (Fig. 8.3). In GACP, species identification should be examined based on both 
morphological and genetic information at introduction time of seeds or seedlings in cultivation or 
determination time of collection site in wild plant collection. The first species identification would be 
the most effective for the botanical raw material of herbal medicinal product. Next species 
identification should be examined based on morphological information as quality test at the raw 
material delivery to factory. Morphological homogeneities of raw materials should be confirmed at 
the quality test in the production company when species cultivated or collected had been identified 
accurately at the introduction time. In factory manufacturing herbal medicinal product, species 
identification of raw materials should be examined as acceptance test based on morphological or as 
necessary genetic information that recommended by FDA (2016) and the United States pharmacopeia 
and the national formulary (United States pharmacopeial convention, 2017). 
 
8.6  Discussion 
Species identification of BRM using molecular markers is effective showing in the chapter 2–7 
in this study. However, in international guide concerning herbal medicinal product manufacturing 
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reviewed, Botanical drug development guidance for industry (FDA, 2016) only recommended species 
identification using molecular markers named as DNA fingerprinting (Table 8.2). Organizations 
concerned herbal medicinal product manufacturing should apply species identification using 
molecular markers on their GACP or GMP to assure quality of herbal medicinal product. 
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Table 8.1.  Comparisons of control strategies among the Part II of PIC/S GMP guidance, EMA GACP 
guideline, WHO GACP guideline and a suitable GACP recommended for herbal 
medicinal product manufacturing. 
 
PIC/S GMP 
(Part II) (2017) 
EMA GACP 
(2006) 
WHO GACP 
(2003) 
A suitable GACP 
1. Introduction 1. Introduction 
2. General 
1. General introduction Introduction 
2. Quality management 3. Quality assurance Including in 4 Quality management  
3. Personnel 4. Personnel and education Including in 2, 3, and 4 Personnel 
4. Buildings and facilities 5. Buildings and Facilities Including in 4 Buildings and Facilities 
5. Process equipment 6. Equipment Including in 4 Process equipment 
6. Documentation and records 7. Documentation Including in 4 Documentation and records 
7. Materials management 8. Seed and Propagation 
material 
Including in 2, 5 Materials management 
8. Production and in-process 
controls 
9. Cultivation 
10. Collection 
11. Harvest 
12. Primary processing 
2. Cultivation 
3. Collection 
4. Common technical aspect 
of GACP 
Production and in-process 
controls 
1)  Cultivation 
2)  Collection 
3)  Harvest 
4)  Primary processing 
9. Packaging and 
identification labeling of 
APIs and intermediates 
13. Packing Including in 4 Packaging and identification 
labeling of BRMs 
10. Storage and distribution 14. Storage and distribution Including in 4 Storage and distribution 
11. Laboratory controls   Laboratory controls 
12. Validation   Validation 
13. Change control   Change control  
14. Rejection and re-use of 
materials 
  Rejection and re-use of 
materials 
15. Complaints and recalls   Complaints and recalls 
16. Contract manufacturers   Including in 4 Contract manufactures 
17. Agents, brokers, traders, 
distributors, repackers 
and relabellers 
  Agents, brokers, traders, 
distributors, repackers and 
relabellers 
18. Specific guidance for 
APIs manufactured by 
cell culture/fermentation 
   
19. APIs for use in clinical 
trials 
  BRMs for use in clinical 
trials 
20. Glossary Glossary Including in 1 Glossary 
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Table 8.2.  Descriptions concerning species identification of botanical raw material in the 
international guidelines. 
 
Guideline Description 
WHO GACP (2003) The botanical identity – scientific name (genus, species, 
subspecies/variety, author, and family) – of each 
medicinal plant under cultivation should be verified and 
recorded. 
EMA GACP (2006) Seeds should be verified botanically, indicating genus, 
species, variety/cultivar/chemotype and origin and 
should be traceable. 
FDA Botanical Drug 
Development Guidance for 
Industry (2016) 
Verification of authenticity with morphology, 
macroscopic and microscopic analysis, and chemical 
analysis. 
DNA fingerprinting may be warranted in cases of 
complicated taxonomy and when identification issues 
related to the botanical raw material exist. 
PIC/S GMP Part II for API 
 (2017) 
At least one test to verify the identity of each batch of 
material should be conducted. 
PIC/S GMP Annex 7  
for herbal medicinal products 
(2017) 
Macro and microscopic examination. 
Suitable identification tests including, where appropriate, 
identification tests for constituents with known 
therapeutic activity, or markers. 
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Figure 8.1.  Concept of the basically management system for the suitable GACP. 
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Figure 8.2.  Life cycle of a herbal medicinal product and events concerning species identification 
of botanical raw materials. 
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Figure 8.3.  Timing of species identification on GACP or GMP. 
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Chapter 9     
 
General consideration 
 
9.1  Availability assessments for the molecular makers using species identification 
Selection of molecular markers for the species identification of botanical raw materials is very 
important. The ITS sequence on nrDNA was very useful for the species identification of botanical raw 
materials because it is easy to amplify at many organism species, has relatively many nucleotide 
polymorphisms (Poczai et al., 2010). In this thesis, ITS was applied to identify Glycyrrhiza species in 
the chapter 3, 4, and 5, or Atractylodes species in the chapter 6. ITS on nrDNA was marked by showing 
two-parental genetic information (Koch et al., 2003). In this thesis, ITS was applied to the cloning 
analysis to identify parent species of Cnidium officinale in the chapter 2, and to detect hybrids within 
Glycyrrhiza species in the chapter 3 and 4, or to detect hybrids within Atractylodes species in the 
chapter 6. Additionally, the ITS sequence which is relatively short length of under 1,000 bp nucleotides 
and is multi copy could be amplified from the fragmented DNA within dried raw materials. In this 
thesis, only ITS could be amplified the step-down PCR (Kawakami et al., 1999) from the Shosoin-
licorice stored since 756AD but rbcL, matK, or trnH–psbA on cpDNA could not be amplified in the 
chapter 5. On the other hand, in the chapter 3, Glycyrrhiza glabra and G. inflata could distinguish by 
matK but not ITS sequences. 
Meanwhile, in this thesis, rbcL was applied to detect inter-genus polymorphism within Apiaceae 
in the chapter 2, or within Araceae in the chapter 7. The rbcL sequences showed inter-genus 
polymorphism as predicted but showed little interspecific polymorphism. In the chapter 7, Arisaema 
amurense, A. erubescens, and A. heterophyllum of original plants of crude drug Tiannanxing could not 
be discriminated by the rbcL sequences.  
In present consequence, ITS would be the first choice for the species identification of botanical 
raw materials. The botanical drug development guidance for industry by FDA and the general chapter 
<563> of United States pharmacopeia recommends ITS, ITS1, ITS2, matK, rbcL, psbA–trnH 
intergenic spacer, cox3, COI (also known as cox1), external transcribed spacer, 18S, 5S, trnL–trnF 
intergenic spacer, and trnL intron as molecular markers for botanical identification (FDA, 2016; 
United States pharmacopeial convention, 2017). 
Most importantly, to select molecular markers for species identifications, many individuals of the 
target and related species identified by their morphological or chemical characteristics and several 
molecular markers should be observed. Within one species, at least 10 individuals by main distribution 
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area should be researched because the species would have unexpected parallel intraspecific or 
interspecific variations such as showed the T-2 genotype of psbA–trnH in the Glycyrrhiza species in 
the chapter 3 (Fig. 3.2). Additionally, the species-specific like polymorphism of the molecular marker 
selected from the genetic research of a few individual would have existed within related species. When 
using molecular markers having high revolution rate like intergenic region, it should be paid attention 
in those case. 
Additionally, the phylogenetic analysis was informative for the selection of species-specific 
genotype, the estimation of phylogenetic relationship among related species, and the detection 
ancestral character (Fig. 3.2). A phylogenetic analysis should be applied when a species identification 
using molecular markers is conducted. 
At present, DNA sequencing technology is developing rapidly by the next-generation sequencing 
technology (NGS). A large amount of DNA sequence can be read in a short time and a low-cost by the 
next generation sequencers. NGS will make it possible to detect more than ten thousands of single 
nucleotide polymorphisms between target organisms. However, those numerous polymorphisms might 
confuse the species identification because the polymorphisms would include many paraphyletic 
variations that become noises for the species identification. Genes or intergenic regions those were 
already applied to taxonomic studies like recommended by above the general chapter <563> of United 
States pharmacopeia (United States pharmacopeial convention, 2017) should be used as molecular 
markers for the species identification. Because those genetic homogeneities in the target taxa and 
evolution rates were already known in those taxonomic studies. Meanwhile, the portable DNA 
sequencer MinION from Oxford Nanopore Technologies is compact and enables a real-time-on-site 
DNA sequencing in the field (Menogon et al., 2017). It is expected that the species identification of 
raw materials of herbal medicinal product can be performed in the field by such as the portable DNA 
sequencer. 
Additionally, a genetically detect technology of a few related or fake raw material in a lot of BRM 
would be needed because, in general, a quality test for BRM on GMP was performed to a extracted, 
triturated, and mixed BRM sample but not to individuals of BRM. The direct DNA sequencing by 
using the Sanger's method could not be detect polymorphisms of a few DNA in a mixture because the 
signal intensity of dNTP fluorescence depends on amounts of the PCR products. In these case, the 
PCR-RFLP showed in the chapter 6 might be effective as a detection method to confirm an existence 
of a few DNA in a mixture. At first, the DNA fragments which have a restriction site in prescribed 
species as BRM are amplified sufficiently by PCR. Next, the DNA fragments are digested by the 
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restriction enzyme. In the observed undigested DNA fragments by an electrophoresis, an existence of 
related or fake raw materials in a mixture are suspected. The undigested DNA fragments should be 
sequenced as appropriate. 
 
9.2  Availability assessments for the species identification using molecular markers for herbal 
medicinal product manufacturing 
Quality assurance of botanical raw material is essential for herbal medicinal product 
manufacturing because the quality of herbal medicinal product is greatly affected by the quality of the 
botanical raw material. The quality of botanical raw material for medicinal product manufacturing 
means the properties of raw material ensuring the medicinal efficacy expected and safety based on the 
ICH guide. The medicinal efficacy is ensured mainly by the kinds, amounts, and their homogeneities 
of the medicinal active constituents included in the raw material. The safety is ensured by toxic and 
contamination control. As a first step to ensure the efficacy and the safety, the accurate species 
identifications of raw materials are essential because at least species prescribed by a regulation such 
as Pharmacopoeia should be used. Therefore, in this thesis, the availability of species identification 
using molecular makers for the quality assurance of raw materials were assessed in some phase of 
botanical raw material production. 
Taxonomic position and scientific name 
In the chapter 2, the accurate taxonomic position of crude drug Senkyu (Cnidium officinale) was 
clarified by the rbcL sequence of cpDNA. In this result, it was revealed that the Japanese Senkyu 
belongs genus Ligusticum where includes Chinese Senkyu (Ligusticum chuanxiong) but not genus 
Cnidium in Umbelliferae. Additionally, it was presumed that Japanese and Chinese Senkyu would be 
hybrids derived from Ligusticum species used medicinally by their ITS cloning analysis. Japanese and 
Chinese Senkyu resemble each other in many morphological and chemical characteristics, too. 
Understanding the accurate taxonomic position and scientific name of the medicinal plant is very 
important to get greater understanding the medicinal property of the raw material. Additionally, the 
rbcL sequence data in each genus of Umbelliferae which includes many kinds of medicinal plants 
were accumulated as basic data for species identification. 
Multiple origins 
In the chapter 3, the species identification of the botanical raw material consisting of multiple 
origins including hybrid was examined. Licorice consists of Glycyrrhiza uralensis, G. glabra, and G. 
inflata, and their hybrids. The Glycyrrhiza species were identified by the phylogenetic analysis based 
on the genotypes of the DNA sequences obtained from the four kinds of molecular markers (ITS, rbcL, 
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matK, and trnH−psbA). Those genotypes include interspecific and intraspecific variations. The 
phylogenetic analysis suggested that G. inflata was closely related with G. glabra than G. uralensis. 
The genotypes obtained were mapped and confirmed their distribution areas in China and their expand 
direction by the phylogenic analysis. The ITS sequence data were effective to identify hybrids because 
ITS on nrDNA showed two-parent genetic information. It was suggested that the species identification 
for the botanical raw materials consisting of multiple origins including hybrid could be possible by 
the combination use of multiple molecular markers. 
Chemical properties 
In the chapter 4, the nine kinds of constituent contents of 205 licorice were researched. Species 
of those 205 licorices were identified by the genotypes observed in the Chapter 4. In this result, the 
already-known species-specific constituents were recognized in the species identified by the genotype, 
too. Additionally, the significant differences of some constituent contents were recognized by the 
Glycyrrhiza species identified by the genotype. It suggested that species identified by the genotype 
and constituent were linked and genotype selection which means only use of medicinal plants having 
the specific genotype would lead to improvement of the medicinal efficacy ensured by the kinds, 
amounts, and their homogeneities of the medicinal active constituents. 
Historical study 
In the chapter 5, Shosoin-licorice stored in Shosoin since 756AD which is the national treasure. 
Species of the Shosoin-licorice was identified as Glycyrrhiza uralensis by the ITS sequences. ITS of 
the Shosoin-licorice stored over 1,200 year could be amplified by the step-down PCR (Kawakami et 
al., 1999). It suggest that species identification using molecular markers would contribute to analyses 
for the historical important crude drugs represented by the Shosoin medicaments and give new insight 
into the crude drug having historical value. 
Development of an easier discriminating method 
In the chapter 6, a discrimination method was developed as a purity test to stop commingling of 
Atractylodes lancea rhizome with Atractylodes rhizome. This method applied the PCR-RFLP method 
without DNA sequencing without a high-priced DNA sequencer. This method is described as 
comparatively easier purity test using molecular markers in the general information of Japanese 
pharmacopoeia (MHLW, 2016f). 
Exclusion of fake raw material 
In the chapter 7, the exclusion of fake raw materials was demonstrated. The discrimination 
between Banxia and Tiannanxing was possible by comparing their rbcL sequences. Consequently, it 
was revealed that small sized Tiannanxing were distributed as Banxia or mixed within Banxia because 
the appearance of small sized Tiannanxing resembled to Banxia. Meanwhile, examination of the rbcL 
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sequence for all individuals in a crude drug lot is impossible because those are too many. In this case, 
appearances of small sized Tiannanxing identified by the rbcL sequences were given to the sorting site 
of the crude drug producing company. Finally, the small sized Tiannanxing were excluded in the 
sorting site. Exclusion of fake raw material required not only discrimination of the crude drugs by the 
genetic information but also translation from the discrimination information to a realistic exclude 
application on GACP or GMP for herbal medicinal product manufacturing. 
 
9.3  Reviewing of GACP and operation procedure of the species identification on GACP or 
GMP for herbal medicinal product manufacturing 
In the chapter 8, a suitable GACP for herbal medicinal product manufacturing was reviewed. In 
the review, it was suggested that the production control of raw materials based on the GMP for 
medicinal product part II by PIC/S (2017b) and the pharmaceutical quality system Q10 by ICH (2008) 
was needed on GACP for herbal medicinal product manufacturing, not but only the EMA (2006) or 
WHO (2003) guidelines. 
In the suitable GACP, species identification of raw material of herbal medicinal product should 
be performed in accordance with PQS. The four phases of (1) Pharmaceutical development, (2) 
Technology transfer, (3) Commercial manufacturing, and (4) Product discontinuation were defined as 
life cycle of herbal medicinal product in PQS. 
In the phase of pharmaceutical development, scientific name (the chapter 2 in this thesis), species 
identification method (the chapter 3 and 7), chemical property (the chapter 4), method of purity test 
(the chapter 6) for raw materials should be confirmed or developed. In the phase of commercial 
manufacturing, the species identification or purity test (the chapter 7) should be examined for raw 
materials of herbal medicinal products. Species identification in this phase should be managed on 
GACP or GMP complained with material management in PIC/S GMP Part II (2017b). The timings 
and methods of the species identification examined on GACP or GMA were illustrated in the chapter 
8 (Fig. 8.2). 
 
9.4  Conclusion 
In quality assurance of botanical raw material, quality means safety and efficacy. Using genetic 
information obtained from suitable molecular markers, species of botanical raw material could be 
identified accurately than using morphological or chemical methods. Use of correct species and 
exclusion of fake raw materials by this species identification using molecular markers prevent toxic 
and contamination derived from botanical raw materials, and assure predicted kinds, amounts, or 
homogeneities of medicinal active constituents. Those means that species identification using 
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molecular makers could be contribute to quality assurance of botanical raw material. The examples 
were presented in this thesis form the chapter 2 to 7. Therefore, species identification using molecular 
marker should be applied systematically in suitable timing on life cycle of herbal medicinal product.  
The suitable timing and operation procedure of species identification for botanical raw material 
were indicated in the chapter 8. The confirmation of scientific name or chemical property, and 
development of method of identification or purity test for a medicinal plant used as a botanical raw 
material performed out of GACP or GMP. Species identification test or purity test for botanical raw 
materials are examined on GACP or GMP. However, species identification using molecular marker 
for all individual in a lot is impossible. Then, the quality assurance of botanical raw material 
complemented by their production process control on GACP is essential. 
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Summary 
 
Kampo medicine is a typical herbal medicinal product in Japan. Quality control of herbal 
medicinal product is difficult than medicinal chemicals because most of their raw materials are made 
from natural products that are a part of plant, animal, fungi, or mineral, and their qualities greatly 
affected by various producing environments of cultivation, harvesting, processing, storage, 
transportation, etc.  
Quality of medicinal products is defined by safety and efficacy. In raw materials of herbal 
medicinal products, the safety is ensured by toxic and contamination control and the efficacy is ensured 
by their chemical properties presented by kinds, amounts, or homogeneities of medicinal active 
constituents. Quality standards of raw materials are provided by the Japanese Pharmacopoeia (MHLW, 
2016a). The standards include origin (species, part, guiding component), description, identification 
(chemical test), purity, total ash, acid-insoluble ash, etc. In the standard items, species identifications 
of raw materials are the first order for quality assurance of raw materials. The compliant species must 
be used as raw materials of herbal medicinal products. 
In the 1980s, the molecular phylogeny has progressed at rapid speed with DNA analysis 
technology. Coupled with that, DNA sequence data of many organisms were accumulated and genetic 
polymorphisms were observed between species, varieties, or cultivars. It was considered that the 
accurate species identification was possible by comparing the species-specific DNA polymorphisms 
of these molecular makers and was helpful for the quality assurance of botanical raw materials (BRMs) 
of herbal medicinal products. 
Therefore, to develop accurate species identification methods using molecular markers and to 
assess their availability, followings were examined; identification of taxonomic position of Cnidium 
rhizome, species identification of Glycyrrhiza roots having multiple origins, chemical properties of 
Glycyrrhiza roots identified species from molecular markers, identification of Glycyrrhiza root stored 
in the Shosoin that is the national treasure in Japan as an application, removal of fake raw materials 
for Pinellia tuber, and development of an easier discrimination method without DNA sequencing for 
Atractylodes rhizome. 
On the other hand, herbal medicinal product manufacturing is controlled on a good manufacturing 
practice (GMP). However, the most of quality controls of BRMs should be controlled on a good 
agricultural and collection practice (GACP) because BRMs qualities are affected greatly by their 
producing environments. Japanese pharmaceutical companies have little GACP experiences but have 
many GMP experiences. They are currently at the phase of thinking about a way to carry out GACP 
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control. Therefore, a suitable GACP for herbal medicinal product manufacturing was proposed by 
reviewing to current international regulations and guidance for herbal medicinal product 
manufacturing, and that when and how the species identification should be examined in the suitable 
GACP. 
As these results, the accurate taxonomic position of Cnidium rhizome was clarified by rbcL 
sequence of cpDNA. The accurate taxonomic position gave correct knowledges concerning medicinal 
properties of Cnidium rhizome.  
The three Glycyrrhiza species and their hybrids were distinguished by the genotypes defined from 
the DNA sequence data of four kinds of molecular markers (rbcL, matK, trnH−psbA and ITS). The 
interspecific and intraspecific genotype variations of the Glycyrrhiza species were observed in China. 
Additionally, the ITS sequence data was effective to identify the hybrids because the ITS sequence of 
nrDNA showed the two-parent genetic information.  
The nine kinds of constituent contents of Glycyrrhiza root were researched by the genotypes 
observed in the above research. In this result, the three already-known species specific constituents 
were recognized in the species identified by the sequence data, too. Additionally, the significant 
differences of the three constituent contents by the three species identified by the genotypes were 
observed. It suggested that a genotype selection which means only use of medicinal plants having the 
specific genotype will lead to improvement of the medicinal efficacy ensured by the kinds, amounts, 
or homogeneities of the medicinal active constituents. Additionally, the Glycyrrhiza root stored in the 
Shosoin was identified G. uralensis by the genetic and chemotaxonomic analyses. 
The fake raw materials of Pinellia tuber could distinguish by the comparing their rbcL sequences. 
However, the species identification using the molecular marker for all botanical raw materials is 
impossible. In this case, the fake raw materials were exclusive by the feedback of the new species-
specific morphological characteristics found by the species identification using the rbcL information 
to the sorting section of the raw material production site. The removal of fake raw materials will lead 
directly to improvement of the safety of botanical raw materials. 
The specified method of Atractylodes roots was developed by the PCR-RFLP without a high-
priced DNA sequencer. This method is described as purity tests on crude drugs using genetic 
information in the general information of Japanese pharmacopoeia (MHLW, 2016f). 
On GACP, the species identification should be conducted to starting materials in cultivation. 
Contamination of fake raw materials should be prevented at the level of seeds, seedlings using the 
cultivation. Additionally, when new seeds or seedlings for the cultivation will be introduced, the 
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species identification must be conducted. About the collection of wild plants, the species identification 
of the wild plants in specified collection areas should be conducted at first. Collections of wild plants 
must be permitted only in the specified areas. Farmers or BRM production companies must cultivate 
or collect the medicinal plants only identified by authorities. Additionally, when BRM will be 
produced from new cultivation or collection areas, the species identification must be conducted.  
On GMP, the species identification using molecular markers should be applied to the acceptance 
testing on GMP because fake raw materials that are undistinguishable from their morphology must be 
removed. However, the acceptance testing to all BRMs in a lot is impossible. The assurance of raw 
material origin complemented by their production process control on GACP is essential. 
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